

**WOUND HEALING AND ANTIFUNGAL PROPERTIES
OF LEMON GRASS**



FAJJAR AZHAR HUSSAIN

Session: 2018-2022

**DEPARTMENT OF ZOOLOGY KINNAIRD
COLLEGE FOR WOMEN, LAHORE, PAKISTAN**

2022

**WOUND HEALING AND ANTIFUNGAL PROPERTIES
OF LEMON GRASS**



**A THESIS SUBMITTED TO KINNAIRD COLLEGE FOR
WOMEN IN FULFILLMENT OF THE REQUIREMENTS FOR THE
DEGREE OF**

BACHELORS OF ZOOLOGY

IN

2022

By

FAJJAR AZHAR HUSSAIN

DEPARTMENT OF ZOOLOGY

KINNAIRD COLLEGE FOR WOMEN, LAHORE

2022

RESEARCH COMPLETION CERTIFICATE

It is certified that **Ms. Fajjar Azhar Hussain** of BS (Hons) (Session 2018-2022), Department of Zoology has carried out this research work entitled “**WOUND HEALING AND ANTIFUNGAL PROPERTIES OF LEMON GRASS**” under my supervision. It is assured that their research work is original and has not yet been published anywhere.

“All changes suggested by examiner during defence are incorporated in this final Copy.”

Supervisor 

Dr. Sana Javaid Awan

Assistant Professor

Department of Zoology



Ms. Shamaila Nadeem

Head of the Department

Kinnaird College for Women, Lahore

Dated:

January 16, 2023

ANTI-PLAGIARISM DECLARATION

I certify that this is our own research work. The work has not, in whole or in part, been presented anywhere else for assessment. Wherever material has been used from other sources, it has been properly acknowledged. The similarity index of the research report is **10%**. If this statement is untrue and I am found guilty of plagiarism, the punitive actions against me should be taken as per Kinnaird Anti-Plagiarism Policy.

Fajjar Azhar Hussain

Registration No: W18BZOL026

Program: BS (Hons) Zoology

Dr. Sana Javaid Awan

Supervisor

Ms. Shamaila Nadeem

Head of the Department

ACKNOWLEDGMENTS

This research work has been done with the help and guidance of many people. First of all, I am Thankful to **ALLAH ALMIGHTY** for all the strength and persistence He bestowed upon me during all this period. I would like to thank my Principal Dr. Rukhsana David and Vice Principal Dr. Nikhat Khan for providing me this opportunity to prove myself. I would like to express my gratitude towards my Head of the Department **Ms. Shamaila Nadeem** for her constant encouragement and supervision.

I would specially like to thank my Supervisor **Dr. Sana Javaid Awan**, for her continuous support throughout my research, for her patience, motivation, enthusiasm and immense knowledge. It was a real privilege for me to share her exceptional scientific knowledge and many other exceptional human qualities.

And a special thanks to my father **Azhar Hussain** and my mother **Parveen Azhar** for their matchless and immeasurable love, care, support, and encouragement throughout my life. My parents always remain my source of inspiration and encouragement. Their unconditional love always gives me warmth, affection, and comfort.

Thanks to my brothers **Waqas Azhar** and **Asad Azhar** for being my support-system throughout my life and especially during this research.

FAJJAR AZHAR HUSSAIN

ABSTRACT

Medicinal Plants have the potential to heal wounds. Lemon grass is one of several plants that have antifungal and wound healing properties. The purpose of this study is to confirm the antifungal and wound healing properties of lemon grass extracts in albino rats with acid-burned injuries. The antifungal potential of lemon grass extracts (20 μ l and 40 μ l) on *Candida albicans* showed remarkable positive results by indicating the inhibition zone. Lemon grass extracts demonstrated best antifungal results at 20 μ l. At 40 μ l, it also showed excellent antifungal results. The wound healing potential of lemon grass extracts was estimated using the wound index measurement, antioxidant estimation, sandwich enzyme-linked immunosorbent assay (ELISA), and histological test. The results obtained were highly significant. Lemon grass demonstrated remarkable wound contraction potential by increasing vascular endothelial growth factor (VEGF) level at different doses (50 and 100 mg/ml). Lemon grass extracts demonstrated the greatest wound healing potential at 100 mg/ml (the VEGF marker increased, while apoptosis decreased) whereas at 50 mg/ml it also demonstrated great wound healing ability. In addition, the histopathological tests also confirmed the wound healing potential of lemon grass extracts. Based on the above results, the extraction, recognition, and purification of phytochemicals from lemon grass extracts is strongly recommended as a viable extension for future research.

TABLE OF CONTENTS

Chapter Title	Page
Research Completion Certificate	I
Anti-plagiarism declaration	II
Acknowledgements	III
Abstract	IV
Table of Contents	V
List of Figures	VIII
List of Tables	XI
List of Abbreviations	XII
1. INTRODUCTION	1
RATIONALE	5
AIM AND OBJECTIVES	6
2. LITERATURE REVIEW	7
2.1 Wound healing	7
2.2 Angiogenesis and VEGF Overview	8
2.3 Wound healing and Angiogenesis	9
2.4 Wound healing and VEGF	12
2.5 Plant Overview	13
2.5.1 Distribution & Habitat	14
2.5.2 Ethnobotany	15
2.5.3 Chemical Composition	15
2.5.4 Lemon grass Properties	18
2.6 Pharmacology	19
2.6.1 Antibacterial effect	19

2.6.2 Antifungal activity	19
2.6.3 An anti-inflammatory effect	19
2.6.4 Antimutagenicity Effect	20
2.6.5 Antioxidant Effects	20
2.6.6 The Hypocholesterolemic Effect	20
3. METHODOLOGY	21
3.1 Plant Powder Preparation	21
3.2 Aqueous Extract Preparation	21
3.3 Antifungal Activity Evaluation	21
3.4 Animal Model	21
3.5 Ethical Clearance	21
3.6 Grouping of rats	23
3.7 Acid Burn Injury on skin of rats	24
3.8 Treatment of rats	26
3.9 Wound Index Measurement	27
3.10 Sandwich ELISA	27
3.11 Antioxidant analysis	29
3.11.1 Estimation of APOX	29
3.11.2 Estimation of SOD	29
3.11.3 Estimation of Glutathione	30
3.11.4 Estimation of Catalase	30
3.12 Histopathology of Skin Sections from Wounds	30
3.13 Statistical Analysis	31
4. RESULTS	35
4.1 Plant powder	35
4.2 Aqueous extract	35

4.3 Antifungal property of lemon grass	36
4.4 Wound Index measurement	38
4.5 ELISA VEGF	40
4.6 ELISA Annexin V	41
4.7 Antioxidant Analysis	42
4.7.1 Estimation of APOX	42
4.7.2 Estimation of SOD	43
4.7.3 Estimation of Glutathione	44
4.7.4 Estimation of Catalase	45
4.8 Histopathology	46
4.8.1 Normal Group	46
4.8.2 Injury Group	47
4.8.3 Placebo 1	47
4.8.4 Treated 1	48
4.8.5 Placebo 2	48
4.8.6 Treated 2	49
5. DISCUSSION	50
CONCLUSION	52
REFERENCES	53

LIST OF FIGURES

Figures	Title	Page
2.1	Wound healing Process	7
2.2	Role of VEGF in the regulation of Wound Repair	13
2.3	Lemon grass Plant	14
2.4	Chemical structures of lemongrass essential oil's principal ingredients	17
3.1	Albino rats	23
3.2	Anaesthesia Injected to Rats before Acid Burn Injury	24
3.3	Rat's Hair Removed by Veet Cream	25
3.4	Filter Paper Soaked in Acid	25
3.5	Acid-burned Area of Rat, Highlighted by Marker	25
3.6	Acid Soaked Filter Paper placed to the shaved region of Rats	26
3.7	Gavage feeding of rat with extract	26
3.8	Wound Index Measurement through Transparency Sheet	27
3.9	VEGF Elisa Plate after adding Substrate	28
3.10	VEGF Elisa Plate after adding Stock Solution	28
3.11	VEGF Elisa Readings	28
3.12	ANNEXIN-V Elisa Plate after adding Substrate	28
3.13	ANNEXIN-V Elisa Plate after adding Stock Solution	29
3.14	ANNEXIN-V Elisa Readings	29
4.1	Grounded lemon grass powder	35
4.2	Filtered lemon grass solution	35
4.3	<i>C. albicans</i> petri dish showing inhibition zone in treated groups	37
4.4	<i>C. albicans</i> petri showing inhibition zone in amphotericin and Fluconazole	37
4.5	Wound measurement of all groups; (a) Normal skin of rat, (b) Injured and untreated rat skin, (c) Placebo (50 mg/ml) given rat skin, (d) Treated (50 mg/ml) given rat skin, (e) Placebo rat skin with dose 100 mg/ml, (f) Treated rat skin with dose 100 mg/ml	38

4.6	Wound index levels in treated groups of rats with selected doses of lemon grass extract decreases as compared to injured groups of rats. Asterisk symbol *** indicates high statistical significance in results (P < 0.001). The mean ± SEM is used to express the values.	39
4.7	VEGF levels in treated groups of rats with selected doses of Lemon grass extracts increases as compared to injured groups of rats. Asterisk symbol *** indicates that the results are highly significant (P < 0.001). The mean ± SEM is used to express the values	40
4.8	Annexin V levels in treated group of rats with selected doses of Lemon grass extract decreased as compared to injured group of rats. *** indicates that the results are highly significant (P < 0.001). The mean ± SEM is used to express the values.	41
4.9	APOX levels in treated group of rats with selected doses of Lemon extract extract in comparison to injured group of rats. *** indicates that there is high statistical significance in the results (P < 0.001). The mean ± SEM is used to express the values.	42
4.10	SOD levels in treated groups of rats with selected doses of Lemon grass extract in comparison to injured group of rats. *** Symbols indicate that the results are highly significant (P < 0.001). The mean ± SEM is used to express the values.	43
4.11	GSH levels in treated groups of rats with selected doses of Lemon grass extract in comparison to injured group of rats. *** Symbols indicate that the results are highly significant (P < 0.001). The mean ± SEM is used to express the values.	44
4.12	CAT levels in treated groups of rats with selected doses of	45

Lemon grass extract in comparison to injured group of rats.

*** Symbols indicate that the results are highly significant ($P < 0.001$). The mean \pm SEM is used to express the values.

4.13	Histopathological diagram of normal skin obtained from rats	46
4.14	Histopathological diagram of injured skin obtained from rats	47
4.15	Histopathological diagram of skin obtained from placebo group 50 mg/ml of rats	47
4.16	Histopathological diagram of skin obtained from treated group 50 mg/ml of rats	48
4.17	Histopathological diagram of skin obtained from placebo group 100 mg/ml of rats	48
4.18	Histopathological diagram of skin obtained from treated group 100 mg/ml of rats	49

LIST OF TABLES

Table	Title	Page No.
2.1	Composition of oil in lemon grass	17
3.1	Samples and control groups of antifungal assessment	22
3.2	Categorization of Rats	23
3.3	Dose, Route and Duration of Anaesthesia given to Rats	24
4.1	Observed antifungal activity	36
4.2	Wound Index Levels (mean \pm SEM) values	40
4.3	VEGF level measured via ELISA (mean \pm SEM) values	41
4.4	Annexin level measured via ELISA (mean \pm SEM) values	42
4.5	Apox levels (mean \pm SEM) values	43
4.6	SOD levels (mean \pm SEM) values	44
4.7	GSH levels (mean \pm SEM) values	45
4.8	CAT levels (mean \pm SEM) values	46

LIST OF ABBREVIATIONS

No.	Abbreviations	Full Form
1	VEGF	Vascular Endothelial Growth Factor
2	HIF	Hypoxia-Inducible Factor
3	PIGF	Placental growth factor
4	PDGF	Platelet-derived growth factor
5	ECM	Extracellular matrix
6	AT	Antiangiogenic
7	bFGF	Basic Fibroblast Growth Factor
8	FDA	Food and Drug Administration
9	Hsp90	Heat Shock Protein 90
10	EOs	Essential oils
11	ELISA	Enzyme-Linked Immunosorbent Assay
12	TBS	Tris Buffered Saline
13	BSA	Bovine Serum Albumin
14	HRP	Horseradish Peroxidase
15	TMB	Tetramethylbenzidine
16	HCL	Hydrochloric Acid
17	NADH	nicotinamide adenine dinucleotide
18	PMS	phenazine methosulphate
19	CAT	Catalase
20	GSH	Glutathione
21	SOD	Superoxide dismutase
22	SEM	Standard Error of the Mean
23	ANOVA	Analysis of variance
24	DTNB	5, 50-dithiobis-(2-nitrobenzoic acid)

CHAPTER 1

INTRODUCTION

The wound healing process, in general, consists of hemostasis, inflammation, proliferation, and remodeling. The cell types engaged in this process include fibroblasts, neutrophils, macrophages, lymphocytes, endothelial cells, and keratinocytes (1). The most apparent aspect of typical wound healing is the formation of a new capillary network through angiogenesis (2). Angiogenesis first develops as a thick but disorganized capillary network in skin wounds and is later reduced to its initial density and structure. A recent study has called into question the long-held belief that increased capillary growth is vital for healing (2). According to new research, usually healed wounds have an abnormally vigorous and mostly ineffective angiogenic response, which could have a negative impact on repair outcomes (3, 4).

The growth of new blood vessels is known as angiogenesis. The endothelial cells, which are present inside the blood vessel walls, move, multiply, and differentiate. The body's chemical signals have an impact on angiogenesis. The receptors on the functional endothelial cells surface are able to bind to some of these signals, particularly VEGF (5). In wound healing, angiogenesis plays an important role because it allows the restoration of normal blood flow, which allows for proper oxygen and nutrient exchange as well as metabolic waste disposal (6). The creation of blood vessels is considered to necessitate the majority of cellular components, extracellular matrix elements, and growth factors that have been identified during wound healing and skin regeneration (7). A protein called VEGF, which is produced in response to injury, is released by a variety of cell types, such as macrophages, fibroblasts, and keratinocytes (8). Hypoxia triggers the transcription factor Hypoxia-Inducible Factor (HIF), which boosts VEGF synthesis (9). Wound healing is delayed by antibodies that reduce VEGF activity or result in conditional gene deletion (10).

The growth of new capillaries during angiogenesis, which results in the production of granulation tissue, is a vital step in the healing of wounds. New capillaries develop in the wound site as granulation tissue three to five days after tissue damage, serving as a matrix for expanding blood vessels, migrating fibroblasts, and developing collagen (11). Wound angiogenesis is affected by growth factors, hypoxia, and inflammation. Chronic wounds are a result of angiogenesis defects that have been identified at the molecular and cellular levels (12).

Angiogenesis, which is the process by which new blood vessels are produced through pre-existing capillaries, is essential for wound healing because it enters the wounded clot and arranges itself into a microvascular network (13). Angiogenesis in wounds is influenced by angiopoietin, fibroblast growth factor, vascular endothelial growth factor, and angiogenic cytokines (14). For the first time, VEGF was found to be an essential growth factor for vascular endothelial cells. Many VEGFs play similar but distinct roles in the formation of new blood vessels (15).

VEGF is one of the most significant growth and survival agents for the endothelium (15). VEGF is involved in vasculogenesis regulation and stimulates angiogenesis and endothelial cell proliferation (16). Endothelial cells do not produce VEGF, which is released by a variety of cells. The first VEGF, VEGF-A, was named the vascular permeability factor because it increased vascular permeability. VEGF, the most essential proangiogenic factor, promotes endothelial cell proliferation, movement, division, and survival, allowing new blood vessels to form. VEGF possesses anti-apoptotic characteristics in addition to boosting cell migration and preventing apoptosis (17).

By enhancing angiogenesis, VEGF influences wound contraction and epidermal repair, the development of granulation tissue, the strength of the healed wound, and the quantity of scar tissue that is formed (14). Even though VEGF has been proven in multiple studies to affect a wide range of wound repair, the overwhelming of VEGF's impacts on wound repair have been associated to its proangiogenic activity (8). Recent findings indicate that cells with VEGFRs, like keratinocytes and macrophages, can interact directly with

VEGF. Normal wound healing produces high quantities of VEGF, which triggers a potent angiogenic response (18).

Lemon grass (*Cymbopogon citratus*) is a tall, fragrant perennial plant with rhizomes and a fiber base that is thickly tufted. Short underground stems with ringed segments and thick clusters of coarse, green, leathery leaves (19). In several regions of the world, it is used to treat digestive problems, mental disorders, fevers, menstrual disorders, rheumatism, and other joint issues. Lemon grass aerial components are commonly utilized in traditional medicine as an infusion or stew (20). The plant's primary phytochemicals are flavonoids, essential oils, and phenolic substances. Saponins, steroids, alkaloids, tannins, and anthraquinones are also found in the plant (21). Lemon grass gets its name from the essential oil in the shoot, which has a lemon-like aroma. The leaves of lemon grass can be used to make paper and cardboard as a cellulose source. In soil supplied with *C. flexuosus* leaves, the root-knot nematode disease was minimized (22).

Lemon grass is a popular fever-relieving plant in the Caribbean. It is applied to the skin as an ointment to treat arthritis and discomfort. An herbal paste made from leaves is used to cure ringworm in India (19). Lemon grass oil is among the essential oils that are most often used in the manufacture of citral. Only the Indian state of Kerala produces and exports lemon grass oil. Lemon grass oil is produced in tiny quantities all over the world, with an annual production of about 1,000 t from a 16,000-hectare farm. It is grown on about 4000 acres in India, with an annual output of around 250 t. The crop is widely grown as live mulch in low, marginal, and waste sites, as well as along bunds. Citral is the beginning ingredient for ionone production (23). Flavors, cosmetics, and perfumes all include ionone. Vitamin A is synthesized with the help of B-ionone. The most common component of oil, citral b, may be a robust b-glucuronidase inhibitor. Bactericides, insect repellants, and medical uses are among the other uses for the oil (21).

Lemon grass has a lot of antioxidants in the form of flavonoids and phenolic chemicals. It has antibacterial and antifungal activities, as well as anti-inflammatory and antioxidant qualities (24). Quercetin, a flavonoid having anti-inflammatory and antioxidant effects, is found in lemon grass (25). In Africa, lemon grass is utilized to treat coronary heart disease (26). When applied topically, lemon grass essential oil possesses antifungal and anti-inflammatory properties (27). Medicine is made from the leaves and oil. Lemon grass can aid in the treatment of fatigue, fever, the common cold, convulsions, nausea, high blood pressure, soreness, and achy joints (rheumatism). It is also used as a mild astringent and to kill bacteria (28).

Lemon grass (*Cymbopogon citratus*) is an important herb that is commonly used in tropical countries, particularly Southeast Asia, in human diets (29). Lemon grass essential oil contains citral, which is needed to produce vitamin A. Lemon grass may contain antifungal qualities, making it a promising choice for future plant disease control programmes targeted at reducing the spread of fungi. Citral and lemongrass oils show potent anti-*Candida* spp. action in vitro (30). Alkaloids, cardiac glycosides, and tannins are some of the phytochemical components of lemon grass oil that are believed to be responsible for its antibacterial and preservation qualities. The activities of lemon grass aqueous extract support its use as an active food supplement, and further research has shown that when subjected to heat during extraction, evaporation, spray drying, and storage, it has minimal cytotoxicity activity (31). Lemon grass powder is also used for wound healing and regeneration because it improves the immune system. It effectively detoxifies body organs and eliminates toxins (32).

This study aims to evaluate the antifungal properties of lemon grass extracts against *Candida albicans* and to determine the potential of lemon grass for skin regeneration of wounds in rats.

RATIONALE

To study the potent antifungal properties of lemon grass and to identify whether it is beneficial in the angiogenesis process or wound healing in acid-burn rats. In preclinical investigations, animal models are utilized to develop cures for various diseases. The whole world prefers neutraceutical remedies to drugs that do significant harm to animals rather than treating them. As a result, the entire globe needs to adopt neutraceutical plants that are more effective, have fewer side effects, and are reasonably inexpensive.

AIM

To evaluate the potency of lemon grass for wound healing and antifungal properties.

OBJECTIVES

- 1.** Preparation of aqueous extract of lemon grass.
- 2.** Evaluation of wound healing in acid burn rats.
- 3.** Evaluation of antifungal Properties of lemon grass.

CHAPTER 2

LITERATURE REVIEW

2.1 Wound healing

A wound is a break in the natural skin epithelial barrier that may change the shape and function of the surrounding normal tissue (33). A contusion, haemorrhage, laceration, or abrasion can all result in a wound (1). The various mechanisms involved in wound healing are complex, vigorous, and well-coordinated. A wound is considered healed when the connective tissues have regenerated and the tissue has been fully re-epithelialized by regrowth, restoring it to its normal structural form and function (34). Chronic, non-healing wounds ensure sustained care because some wounds do not heal promptly (35). Acute wound healing, a closely regulated, systemic series of overlapping events, requires the coordinated performance of a number of cellular activities, including chemotaxis, extracellular matrix production, mitogenesis, and phagocytosis (36). The processes, which are set off by tissue damage, can be categorized into four stages: haemostasis, inflammation, proliferation, and remodeling (37).




Figure 2.1: Wound healing Process (38)

2.2 Angiogenesis and VEGF Overview

In recent writings, British surgeon John Hunter frequently mentions the initial appearance of the term "angiogenesis" (39). According to Rogers et al, Van de Kolk got several intriguing results: When Schroeder Van der Kolk performed the first injection tests in neoplastic tissue in 1826, he remarked on the differences in blood supply between spontaneous and transplanted tumours (40). With only 40 papers published in 1980 and about 6000 in 2010, the field of angiogenesis has changed dramatically in the course of recent years. According to the Angiogenesis Foundation, angiogenic therapy has the potential to enhance the lives of at least 1 billion people around the world (5).

Angiogenesis refers to the mechanical and chemical processes that result in the formation of new blood vessels from existing ones (41-43). A systematic study by Bonanno and Iurlaro et al. confirmed the extracellular matrix (ECM) is required for angiogenesis at all stages (44). Angiogenesis is the term used by Adair and Montani to denote the development of new blood vessels. Numerous physiological and pathological events depend on this process (tumor growth, arthritis, diabetic retinopathy) (45). Folkman et al. were the first to isolate an angiogenic factor from Walker 256 tumour cells in the ascites form (46). An angiogenic factor generated by activated macrophages was described by Polverini et al. (47). Castellot (48) discovered a substance that promotes capillary endothelial cell proliferation in vitro. Luttuna and Autiero et al. suggest that other molecules, such as PlGF (VEGF homologue), contribute to angiogenesis in diseases while having no effect on quiescent capillaries in healthy organs. As a result, therapeutic prospects for the development of safe anti-angiogenic medicines have emerged (5). Shweiki et al. proposed the finding that hypoxia, which occurs during tumour progression and ischaemia, regulates VEGF expression through transcription (49). The importance of vascular endothelial growth factor in the development of blood vessels is emphasized by the aberrant blood vessel formation and neonatal deaths that result from the deletion of a single VEGF-A allele (15, 50).

Many pathologic situations, including wound healing, chronic inflammation, restenosis, atherosclerosis, and malignancies cause angiogenesis. The VEGF protein family is

universally recognized as being the most significant proteins involved in the growth of the vasculature; they have roles in vasculogenesis, lymphangiogenesis, and angiogenesis in both normal and malignant situations (51-54).

Recent research has shown a previously unreported link between the nervous system and angiogenesis (55). For instance, Mukoyama et al. (56) discovered that in the epidermis of the embryonic mouse limb, the pattern of arterial blood vessel formation and branching is regulated by the local VEGF-A release by sensory neurons (57). The neurotransmitter dopamine inhibits VEGF-A induced angiogenesis, (58) whereas Netrin-1, an angiogenic molecule that magnifies VEGF-A effects, is the axonal attractant (59).

Recent studies have shown that tissue factor can influence angiogenesis through non-clotting routes. First, tissue factor increases VEGF-A synthesis while decreasing thrombospondin-2 transcription, which prevents angiogenesis (60-62). Since it increases the synthesis of tissue factors, tissue factor-induced overexpression of VEGF-A has the potential to promote a self-sustaining feedback mechanism (63, 64). Along with its capacity to produce fibrin and aid in clotting, thrombin has been shown to have a substantial impact on angiogenesis (65). Antiangiogenic effects are also found in thrombin (65). It degrades antithrombin (AT) in vitro and in vivo to create a powerful inhibitor of angiogenesis, bFGF-induced endothelial cell proliferation, and VEGF-A (66). Antiangiogenic AT, domain 5 of the high-molecular-weight kininogen, and prothrombin fragments 1 and 2 are cryptic antiangiogenic fragment-containing proteins that function in the hemostatic system (67).

2.3 Wound healing and Angiogenesis

Wound repair and regeneration rely heavily on angiogenesis. An increase in interest in angiogenesis research has resulted in the understanding required to generate the first anti-angiogenic drugs (12). In 1972, the concept of “antiangiogenesis” as a possible treatment method was proposed (68). Antiangiogenic therapy preclinical investigations and clinical trials, such as the treatment of hemangioma with interferon alfa-2a, indicate guidelines for such a potential treatment in the future care of cancer patients (69). According to

Bauer, the ability of several recombinant angiogenic growth factors to speed healing has been investigated (11). According to Crovetti and Martinelli, only PDGF is accessible as a topical wound ointment that has been authorised by the FDA (70). Falanga claims that VEGF-A works against the benefits of the VEGF-A gene by speeding up healing and angiogenesis in ischemic ulcers. Oral bFGF stimulated angiogenesis and accelerated healing of duodenal ulcers in mice in pre-test trials (71). Studies on VEGF's role in wound healing began soon after it was discovered and described as a proangiogenic agent (18, 72).

According to Kumar et al., Honnegowda, angiogenesis is vital for the healing of wounds because it penetrates the wound clot and causes the capillaries there to grow new blood vessels, creating a microvascular network in the granulation tissue. Powerful angiogenic cytokines are all potent in wound angiogenesis, angiopoietin, endothelial growth factor, and fibroblasts (7). The researchers also revealed that extracellular Hsp90 is located in the granulation of damaged skin tissues on blood vessels and in a wound healing model in vivo, it enhances angiogenesis. According to the findings, Hsp90 can be released by endothelial cell activation and is a positive angiogenesis regulator, suggesting Hsp90 can be used as a wound repair stimulator (73).

Studies by Arnold and West show that angiogenesis is a critical step in wound healing (74). Bao, Kodra et al proposed that VEGF promotes collagen deposition and epithelialization in addition to wound healing through angiogenesis. More research into the chemical, whether through proteins or other delivery mechanisms like genetic therapies, will improve its therapeutic potential to speed up the healing of chronic wounds (8). The transport of oxygen from surrounding tissue and the circulation from newly-created blood vessels to the wound bed is a crucial part of effective cure (75). Guerra, Belinha et al. proved that Angiogenesis facilitates the restoration of regular blood flow, adequate nutrient and oxygen exchange, and the removal of waste substances, all of which are essential for cell viability and proliferation (76).

The establishment of a new capillary network by angiogenesis is one of the most noticeable characteristics of normal healing. Angiogenesis begins in skin wounds with

the development of an irregular, thick capillary network that is later thinned to its original thickness (77). The wound on the skin that is regularly healing is an excellent model for both vigorous capillary growth and regulated capillary regression (78, 79). When a wound cools, new capillaries form quickly, forming more connections to the new thick blood vessels than normal tissue (80). A strong and active angiogenic response is required for healing process (2). Due to cellular migration, development, and metabolic activity, injuries do create a need for oxygen and nutrients. Despite this, at least eight distinct investigations have revealed that when angiogenesis is decreased, skin wound closure is fully normal. Many approaches have been utilized in this research to minimize wound angiogenesis, including the use of anti-VEGF antibodies, antiangiogenic drugs, and integrin signaling blockage (81-84). Because of the link between vigorous angiogenesis and scar development, antiangiogenic therapy has been proposed as a way to minimize scar formation (85-88). Higher microvascular content in the production of hypertrophic scars has been associated to this condition (89, 90). Furthermore, keloids, a particularly strong kind of skin scarring, have been shown to have a high amount of angiogenesis (88). In tissues other than the skin, such as the liver and the lungs, fibrosis has been linked to angiogenesis (91, 92).

Animal studies have shown that pharmacologic angiogenesis suppression can improve healing outcomes, even if human trials of antiangiogenic treatments for improved wound healing have not yet been conducted. When VEGF was blocked with an antibody, the peak wound vascularity and scar width in mature skin wounds in mice were both significantly reduced (85).

Skin wounds are healed step by step throughout the acute stages of healing, beginning with hemostasis and inflammation. Then there are phases of increased cellular proliferation, ECM formation and remodeling, and scar formation (93, 94). Angiogenesis plays a significant role in the proliferative phase of the healing process (5). The number of blood vessels at the injured site briefly increases as a result of this process. Since the transfer of oxygen and nutrients through these blood vessels is essential to the healing process, angiogenesis issues are intimately related to a delay in the healing of wounds. A

variety of lipid mediators, growth factors, and cytokines produced in response to injury may cause angiogenesis. The most significant proangiogenic mediator is vascular endothelial growth factor, which is thought to be necessary for an efficient healing process. VEGF promotes angiogenesis, (95) which affects wound contraction, epidermal repair, the formation of granulation tissue, and the efficiency of the repair. The majority of VEGF effects during wound repair have been credited to its proangiogenic activity.

2.4 Wound healing and VEGF

During the normal healing process, large concentrations of VEGF are produced, which triggers a potent angiogenic response. (96). People with persistent chronic ulcers, such as diabetics, have very low VEGF protein levels. Inadequate wound vascularization due to low VEGF activity is most likely a factor in these repair delays. Furthermore, medicines that inhibit the function of VEGF, which are used to treat a variety of cancers increase the risk of wound healing problems (97).

VEGF is one of the main proangiogenic mediators in healing process. The increase in VEGF following damage is likely due to multiple cellular sources. Damaged skin produces more VEGF, which is typically expressed at low levels by epidermal keratinocytes (98). Research has shown that keratinocytes release VEGF early in the scar healing process (72, 99). New research reveals that keratinocytes create VEGF during the healing process (100). VEGF is expressed in injured skin by activated fibroblasts, macrophages, and mast cells (99). At various stages after injury, myeloid cells were discovered to be a significant producer of VEGF (100), which is produced by both keratinocytes and myeloid cells. One of the elements that promote the growth of VEGF during the healing of wounds is hypoxia. The VEGF gene is produced as a result of the transcription factor HIF being activated by low oxygen levels in injured skin (101). VEGF production by keratinocytes has been shown to be stimulated by oxidants such as hydrogen peroxide produced in response to injury.




Figure 2.2: Role of vascular endothelial growth factor (VEGF) in the regulation of Wound Repair (18)

2.5 Plant Overview

Lemon grass is a tropical perennial that produces fragrant oil. Lemon grass gets its name from the essential oil in the shoot, which has a lemon-like aroma. The herb is believed to have originated in Asia and Australia. In Pakistan, lemon grass is found in Baltistan, Jammu Kashmir, Hunza and Chitral valley (21, 102). The green leaves of this grass have a pronounced citrus aroma when crushed, earning it the name (103).

Lemon grass (globally known as *Cymbopogon citratus*) belongs to the Poaceae family (24). The height of *C. citratus*, a tufted, robust perennial grass, reaches around 2 metres. The leaves are lanceolate and linear. It blooms profusely. The inflorescence is a drooping panicle with paired spikes on very large and well-branched tertiary stems. The spikelets come in pairs, one sessile and one pedicellate. The sessile spikelet is an awned bisexual floret, while the staminate floret is awnless (21). At end of its life cycle, this plant produces flowers. Flowering has never been seen during cultivation. The inflorescence is a large spike that is one metre in length. Decompound spatheate panicles with a length of 30 to 60 cm bear flowers. The rhizome, which develops new suckers, rises vertically as tillers to create dense clusters (104, 105).




Figure 2.3: Lemon grass Plant (102)

2.5.1 Distribution & Habitat

Lemon grass grows wild in North America, South America, Africa, Australia, Europe, and among other places (22). It is grown in China, Bangladesh, Thailand, and India, and is widely cultivated throughout the tropics. Northern regions including Jammu & Kashmir, Punjab, Rajasthan, Delhi, and Bengal are habitat to native lemongrass plants (106). Lemon grass is grown extensively in the Chinnar wildlife reserve in India's Western Ghats (19).

This grass lovely lemon scent has long been employed in perfumery and associated products, as well as in the culinary industry (102). Thai and Vietnamese cuisine pioneered the use of lemon grass. It is frequently used to flavour tea in nations in Africa and South America. It can be found in both alcoholic and non-alcoholic drinks (107). It also functions as a sedative, diuretic, antipyretic, and anti-inflammatory in Ayurveda (108). Lemon grass is used medicinally by a variety of ethnic groups (103). Brazilians regularly use lemon grass tea as an anti-inflammatory, analgesic, antispasmodic, antipyretic, sedative, and diuretic (109). In Argentina, it is used to treat sore throats. In Cuba, it is used to treat catarrh, rheumatism, and lower blood pressure (110). Lemon

grass also has anti-cancer, anti-carcinogenic, anti-fungal, anti-bacterial, anti-protozoal, antioxidant, antitussive, antiseptic, and anti-rheumatic effects (111).

2.5.2 Ethnobotany

The commercially valuable essential oils produced by the *Cymbopogon citratus* plant are a common ingredient in traditional medicine and food processing. People are becoming more aware of health issues as a result of arrival of the new ailments. Due to the unfavorable side effects of synthetic medications, treatment with plant-based medicine looks to be an alternative to artificial therapy (112). Lemon grass is used to cure a variety of ailments, including coughs, elephantiasis, the pneumonia, gingivitis, malaria, flu, headaches, leprosy, ophthalmology, and vascular issues. Lemon grass also has antibacterial and antifungal effects. When combined with pepper, it serves as a natural cure for nausea and menstruation issues. Lemon grass is an organic purifier that promotes more detoxification of the liver, kidneys, pancreas, digestive tract, and bladder. It reduces lipids, uric acid, cholesterol, and other body toxins in addition to enhancing lactation, digestion, and blood flow. It also lessens indigestion and gastroenteritis. Lemon grass is also used as a muscle and tissue toner and is thought to help enhance the skin by reducing acne and pimples. Additionally, it may lower blood pressure. The cancer prevention benefits of lemon grass were identified (105, 113).

The biological characteristics of lemon grass and their associations with developments in medicine, gastronomy, cosmetics, and agriculture serve as the basis for most of its uses. The efficient use of lemon grass as a raw material in the production of paper (114), as an adsorbent (115), a fundamental constitute in composites, (116) and in the production of silica has been reported (117).

2.5.3 Chemical Composition

Cellulose (39.5%), hemicellulose (22.6%), and lignin (28.5%) are the three main components of lemon grass (118, 119). Lemon grass is a hydrocarbon that is mostly made up of carbon and oxygen. Hemicellulose is mainly amorphous and has just a small amount of crystalline material, whereas cellulose has a three-dimensional structure with

glossy and amorphous regions. The degree of polymerization, which can range from 100 to 10,000 for cellulose and less than 200 for hemicellulose, is another key distinction between the two (120). Lignin is a nonlinear, amorphous, heterogeneous polymer that binds cellulose components together in three dimensions (121). 1, 4-glucofuranose units are found in cellulose. Xylose, galactose, arabinose, and mannose are subunits of hemicellulose, while guaiacyl, syringyl, and p-hydroxyphenyl are subunits of lignin (122).

Lemon grass oil concentration varies based on genetics, growth zone, culture, and agronomic treatment. 1-2 % of the plant's weight is used to extract essential oils (EOs) (123). On the other hand, the drying process can have an effect on the composition. Despite the fact that dehydrated oil has a high concentration of citral, which is used to evaluate the oil level, oven-drying leaves can produce more EO than sun-drying or shading techniques (124).

Geraniol and nerol, also referred to as trans-citral and cis-citral, are two stereoisomeric mono-terpene aldehydes that make up citral (125). On average, citral oil makes up more than 45% of lemon grass oil; however, the proportion varies greatly between animal species. Citral content ranges from 30-94 percent in East Indian lemon grass (108, 126). According to research, terpenes, alcohol, ketones, and esters are among the hydrocarbons discovered in the production of EO (127). Phytochemicals such as anthraquinones, phenols, flavonoids, tannins, saponins, and alkaloids have been found in lemon grass. There are also trace amounts of citronellol, terpineol, borneol, kaempferol, nerol, luteolin, caffeic acid, chlorogenic acid, glycosides, catechol, geranyl acetate, valerichyde, and methylheptenone fumesol (108, 128, 129). Lemon grass has been shown to contain phytochemicals, orientin, swertiajaponin, and isoscoparin (130, 131). The figure depicts high geraniol and nerol concentrations as well as low levels of myrcene, limonene, nerol, citronellol, and geraniol (132, 133). Some of the minerals that have been discovered are silica (9.02%), calcium (25.6%), potassium (54.02%), and phosphorus (1.57%) (117). Along with protein, carbs, and fat, there are also niacin, vitamins A, C, and E, folate, riboflavin, and pyridoxine (134).




Figure 2.4: Chemical structures of lemon grass essential oil's principal ingredients (135)

Table 2.1: Composition of oil in lemon grass

Oil Composition	Components (%)
Alpha Pinene	0.07
Borneol	0.1-0.4
Beta Pinene	0.04
Beta caryophyllene	Traces
Citral alpha	40.8
Citral beta	32
Citronellal	2.10
Geraniol	3.04
Geranyl acetate	0.83
Limonene	Traces
Linalyl acetate	0.1
Myrcene	0.72
Nerol	4.18
Terpinolene	1.23
Terpinol	0.45

2.5.4 Lemongrass Properties

According to scientific research, lemon grass is an antifungal, antibacterial, and antiprotozoal agent (114, 136-143). Several investigations have also verified lemon grass anti-nociceptive and anti-inflammatory properties (144-146).

The biological activity of various components in lemon grass essential oil has been investigated in a number of studies. Citral and geraniol have antifungal properties, and the presence of myrcene boosts that activity even more (147). Lemon grass antibacterial activity was attributed to cinnamic aldehydes, linalool, alkaloids, and phenols (148). Lemon grass antibiotic activity is more likely due to the combination activities of its constituents than a single element (111).

Lemon grass has been proven to have anti-tumor, anti-carcinogenic (149), anti-mutagenic (150), anti-amoebic (151), anti-diarrhoeal (152), anti-filarial (153), larvicidal and ascaricidal activities (154).

The entire plant's lemon essence can be efficiently added to traditional cuisines, and its aqueous extract is frequently used to make fragrant drinks. It was widely used in traditional medicines. Lemon grass tea was widely used for its antibacterial, antifever, antidyspeptic, carminative, and anti-inflammatory properties, making it popular in South American, Asian, and West African nations. Others include stomachic agents, diuretics, analgesics, spasmolytics, antipyretics, and febrifuges (21).

In recent articles, it is stated that lemon grass has high vitamin C content, and its oil has antifungal properties against phytopathogenic fungi (155, 156). The extract of this plant proved effective in lowering blood cholesterol levels since it contained an active ingredient and raw fiber (112). (157) Lemon grass has been discovered to contain antioxidants, and dried lemon grass has more phenols and flavonoids than fresh lemons (158). In this research, both in vitro and in vivo evaluations of lemon oil's remarkable anti-fermentation properties were conducted. This essential oil is deemed toxicologically acceptable for use in food preservation because of its vital role in avoiding lemon grass oil fermentation in mixed juices (159). Cristiane de Bona da Silva gave a paper on this

topic. The report states that numerous essential oils have been investigated for their potential to inhibit mycotic growth both in vivo and in vitro, with some demonstrating potential antifungal properties (160). Lemon grass oil has been studied for its antifungal properties against dermatophyte species and *Candida albicans*, two forms of human illnesses (161, 162).

2.6 Pharmacology

2.6.1 Antibacterial Effect

Lemon grass also possesses antibacterial properties and is used as an herbicides and pesticides. *Salmonella paratyphi*, *Shigella flexneri*, *Staphylococcus aureus*, *Shigella flexneri*, *Bacillus subtilis*, and *Escherichia coli* were all successfully eradicated by the chromatographic extract of the oil on an agar plate (163, 164). Myrcene, the third component, has no antibacterial activity by itself, whereas both the geranial and neral citral components possess antibacterial activity against both gram-positive and gram-negative bacteria (163). The volatile oil extract was still functional after being oxidized with active oxygen (145, 165-167).

2.6.2 Antifungal Activity

Lemon grass is effective against *Epidermophyton floccosum*, *Trichophyton mentagrophytes*, *Trichophyton rubrum*, and *Microsporum gypseum* (168). Lemon grass oil has also been shown to be effective against keratinophilic fungus, food storage fungi, (169, 170) and 32 ringworm species (171). Lemon grass is frequently used in traditional medicine as an antibacterial agent, and its essential oils, which are combinations of naturally occurring volatile molecules that are obtained through distillation, have long been known to have antifungal properties (146).

2.6.3 An anti-inflammatory effect

Lemon grass tea contains several compounds and essential oil extracts that possess anti-inflammatory effects (31).

2.6.4 Antimutagenicity Effect

In a number of species, lemon grass ethanolic extract has an anti-carcinogenic action (150, 172, 173) and it prevents lung metastasis in mice by reducing the development of fibrosarcoma cells implanted in the lungs (174). It has been shown that the plant extract prevents the growth of DNA adducts and abnormal crypt foci brought on by azoxymethane in the rat colon (149). In 344 male Fischer rats, the plant extract had a suppressive effect on the development of the earliest stages of hepatocarcinogenesis after diethylnitrosamine exposure (175). Lemon grass was reported to have a promising anticancer activity (176).

2.6.5 Antioxidant Effects

Citrus juices and fruits are good sources of antioxidants, which include ascorbic acid, flavonoids, and phenolic compounds (130). Citrus fruits, such as lemon, have the highest antioxidant activity. Lemon grass extract and essential oil have been reported to have strong antioxidant properties (177).

2.6.6 The Hypocholesterolemic Effect

Costa et al. (178) reported the safety of lemon grass intake at the doses used in folk medicine and indicated the beneficial effect of reducing the blood cholesterol level. In a 2015 research study, the mice that received the plant extract had much lower levels of elevated cholesterol. It was determined that this decline was dosage-dependent. This demonstrates the extract's potential to lower cholesterol (179).

CHAPTER 3

METHODOLOGY

3.1 Plant Powder Preparation

Lemon grass is a tropical plant with gently fragrant leaves that is native to South and Southeast Asia (102). A fresh lemon grass plant was taken and ground to a fine powder.

3.2 Aqueous Extract Preparation

Aqueous plant extract was prepared by dissolving 10 grammes of plant powder in 100 millilitres of water and filtering the solution after two days. The filtered extract containing water-soluble fractions was evaporated using petri dishes placed in the refrigerator (180).

3.3 Antifungal Activity Evaluation

3.3.1 Preparation of culture media

According to the manufacturer's instruction, Ampoule containing freeze dried form of the microorganism was opened and the contents were added to the Yeast Extract Peptone Dextrose broth which was incubated at $25 \pm 2^\circ\text{C}$ for 72 h (181). The 30 ml of molten sterile agar was poured aseptically in each four sterile petri plates and were allowed to solidify at room temperature. Hundred microliter of inoculum was spread with a sterile steel spreader to prepare a lawn of microorganism.

3.3.2 Ditch plate method

Four wells on two plates were set up. The wells were assigned numbers between 1 and 8. Using a micropipette, a predetermined volume (250 ul) of the appropriate stock solution of lemon grass extract was added to each well. Then three wells were made similarly on the fourth plate. Fluconazole served as the positive control, while the same plate also included 50% DMSO and sterile distilled water to serve as the negative controls. The

plates were all then incubated for 24 hours at 25 °C while standing upright. The entire process was carried out twice. After 24 and 48 hours, the inhibition zones were measured on the underside of the plates using the Hi-Media zone scale.

Table 3.1: Samples and control groups incorporated in the 8 compartments of petri dish

Group 1	Normal
Group 2	Injection water 20 µl
Group 3	Treated-20 µl
Group 4	Treated-40 µl
Group 5	Amphotericin B
Group 6	Fluconazole
Group 7	Placebo-20 µl
Group 8	Placebo-40 µl

3.4 Animal Model

Albino rats (100-120g) were received 14 days before the experiment from the animal house of the University of Lahore. They were provided with proper food and water in their cages.

3.5 Ethical Clearance

For using animal (albino rats) Ethical Clearance was taken from Ethical Committee of Kinnaird College for Women, Lahore.



Figure 3.1: Albino rats

3.6 Grouping of rats

Albino rats were separated into 6 groups, each with $n = 3$ rats in each group. One group of rats was not given any injury while the other 5 groups were given acid burn injury.

Table 3.2: Categorization of rats

No.	Group Name	Group detail
1	Normal rats	Rats given no injury
2	Untreated rats	Injured rats left untreated
3	Placebo (Plac) 1	Injured rats treated with 50 mg/ml placebo
4	Treated 1	Injured rats treated with 50 mg/ml aqueous extract
5	Placebo (Plac) 2	Injured rats treated with 100 mg/ml placebo
6	Treated 2	Injured rats treated with 100 mg/ml aqueous extract

3.7 Acid Burn Injury on Skin of Rats

First the rats were anesthetized with combined injected ketamine/xylazine.

Table 3.3: Dose, Route and Duration of Anesthesia given to Rats before Acid Burn Injury

Drug	Dose	Route	Duration of Anesthesia
Ketamine + xylazine (Rompun®)	40-90 mg/kg ket + 5-10mg/kg xyl.	IP, SQ	45-90 minutes

Acid burn injury was conducted to check influence of the lemon grass extract on healing of the wound or if the lemon grass extract can be used for the treatment and cure of burn injury. Total number of rats (n=6) out of which 1 was normal (with no injury) and five (n=5) were anaesthetized with xylazene and ketamine solution (anaesthesia) to whom acid burn injury were given (Duan et al., 2009).




Figure 3.2: Anaesthesia Injected to Rats before Acid Burn Injury.

The dorsal side hairs of rats were removed.



Figure 3.3: Rat's Hair Removed by Veet Cream

Small cube shaped filter papers (2x2cm) were soaked in acid for few seconds.



Figure 3.4: Filter Paper Soaked in Acid

Acid burned area of rats then highlighted by marker.



Figure 3.5: Acid-burned Area of Rat, Highlighted by Marker

Acid-soaked filter papers were then applied to the shaved region for 20 seconds as directed. Two injuries were given to each rat.



Figure 3.6: Acid Soaked Filter Paper was placed to the shaved region of Rats

3.8 Treatment of rats

One of these five rat groups was not given any treatment. Two groups were treated with the aqueous extract of lemon grass in different concentrations (50mg/ml and 100mg/ml), and normal saline in different concentrations (50mg/ml and 100mg/ml) was given to the remaining two groups, with the help of gavage tube (181).



Figure 3.7: Gavage feeding of rat with extract

3.9 Wound Index Measurement

The reduction in the wound was measured by wound index measurement assay on days 7. Transparency clear sheet of plastic was placed on sedated rats wounds with the ventral side down. A pointer was used to draw a line through the wounded region on the sheet (182). The initial and current wound sizes were used to compute the percentage reduction in wound size.




Figure 3.8: Wound Index Measurement through Transparency Sheet

3.10 Sandwich ELISA

ELISA was performed on the blood sample, taken from the body of rat after sacrifice. Rat's blood was calculated and the serum was isolated from that blood and then this serum was subjected to ELISA for skin regeneration and apoptosis.

In a 96-well plate, ELISA was used to test VEGF and annexin V. The VEGF and annexin V antibodies were applied to the plate and incubated for 100 minutes. Following 3 times TBS-T washes, 1% BSA was applied for a 35-minute blocking period. After blocking, each well was loaded with 210 μ l of sample (serum taken from the treated rat's blood) and incubated for seventy minutes. The sample was taken out & thoroughly washed 3 times before being incubated for 115 minutes at 37°C with a HRP (Horse raddish peroxidase) conjugated donkey anti-rabbit secondary antibody. After washing for 10

minutes, 110 µl of chromogenic solution 3, 3', 5, 5'-tetramethylbenzidine (TMB) and H₂SO₄ was added to terminate the reaction and at 450nm, absorbance was taken (183).




Figure 3.9: VEGF Elisa Plate after adding Substrate




Figure 3.10: VEGF Elisa Plate after adding Stock Solution

Sample(1)	Blank(2)	-NC(3)	+PC(4)	Std(5)	QC(6)	Clear(7)
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31	32	33	34	35
36	37	38	39	40	41	42
43	44	45	46	47	48	49
50	51	52	53	54	55	56
57	58	59	60	61	62	63
64	65	66	67	68	69	70
71	72	73	74	75	76	77
78	79	80	81	82	83	84
85	86	87	88	89	90	91
92	93	94	95	96	97	98
99	100	101	102	103	104	105
106	107	108	109	110	111	112

Figure 3.11: VEGF Elisa Readings




Figure 3.12: Annexin V Elisa Plate after adding Substrate

8.3), and 0.3 ml of nitrobluetetrazolium (300 IM), and with the incorporation of 0.2ml of nicotinamide adenine dinucleotide (NADH), the reaction was initiated. After 90 seconds of incubation at 30 C, the reaction was stopped by adding 0.1 mL glacial acetic acid. The reaction mixture was rapidly agitated with 4.0 mL of butanol. After a 10-minute incubation period, the mixture was centrifuged for 5 minutes at 2000 rpm for 5 minutes. The upper butanol layer's absorbance was estimated at 560 nm.

3.11.3 Glutathione measurement

Using the Beutler et al. approach, the diminished amount of glutathione (GSH) in cell culture medium is assessed (186). 0.5 ml of cell culture media was loaded up in a test tube from both gatherings, 0.25 ml (5, 50-dithiobis-(2-nitrobenzoic acid) or DTNB and 2.0 ml of disodium hydrogen phosphate cradle (0.3 M). After 15 minutes of incubation, the absorbance was measured using a spectrophotometer at 412 nm.

3.11.4 Assessment of catalase

The activity of catalase is estimated using the Sinha method (187). An amalgam of 0.1 ml of cell culture medium, 0.4 ml H₂O₂, and 1.0 ml phosphate cushion was prepared. The reaction was halted with the addition of 2.0 mL of dichromate acetic acid reagent. After 10 minutes in a bubbling water shower, the samples cooled and at 530nm, the absorbance was estimated.

3.12 Histopathology of Skin Sections from Wounds


Skin samples of 0.5 cm² were collected from the injured area 7 and fixed in a 10% neutral buffer formalin solution after slaughtering an animal. The specimens were then sliced into 46 microns thicker portions and stained with hematoxylin and cosine. Then they were dehydrated and washed into paraffin bedding (188).

3.13 Statistical Analysis


The whole set of experiments was used in a triplicate manner and expressed as mean \pm EMS. One-way ANOVA and Bonferroni's test were applied for statistical analysis of different groups. To draw graphs for the quantitative data achieved from molecular analysis, Prism software has been used. For statistical analyses, P value \leq 0.001 was considered significant. Software Endnote X7 for adding reference has been used.

PLAN OF WORK


IN-VITRO ASSAYS





Antifungal Assay



IN-VIVO ASSAYS





CHAPTER 4

RESULTS

4.1 Plant powder

Lemon grass was grounded and sieved to form a yellow-colored plant powder.



Figure 4.1: Lemon grass Powder

4.2 Aqueous extract

The mixture of weighted lemon powder and water was filtered after 2 days and then evaporated to obtain the extract of lemon grass.



Figure 4.2: Filtered lemon grass powder

4.3 Antifungal property of lemon grass

The purpose of this assay was to determine the antifungal property of lemon grass extracts. Lemon grass extracts was tested against *Candida albicans* and the result obtained was highly significant.

Table 4.1: Observed Antifungal Activity

No.	Groups	Antifungal activity
1	Normal	-ve
2	Injection water 20 μ l	-ve
3	Treated-20 μ l	+ve
4	Treated-40 μ l	++ve
5	Amphotericin B	++ve
6	Fluconazole	+ve
7	Placebo-20 μ l	-ve
8	Placebo-40 μ l	-ve




Figure 4.3: *C. albicans* petri dish showing inhibition zone in treated group (40 µl)




Figure 4.4: *C. albicans* petri dish showing inhibition zones in amphotericin B, and Fluconazole

4.4 Wound Index measurement




Figure 4.5: A shows normal non-injured rat skin, B shows injured non-treated, C shows placebo 1, D shows treated rats 1, E shows placebo 2 and F shows treated 2

This graphical data shows that the group of rats treated with lemon grass plant extract in comparison to injured groups shows significant values of wound index and an increase in wound contraction. The results were estimated by applying one-way ANOVA using graph pad.




Figure 4.6: Wound index levels in treated groups of rats with selected doses of Lemon grass extract decreases as compared to injured groups of rats. Asterisk symbol *** indicates high statistical significance in results ($P < 0.001$). The mean \pm SEM is used to express the values.

Table 4.2: Graphical results values of Wound index expressed in mean \pm SEM

	Normal	Injured	Placebo 50 mg/ml	Treated 50 mg/ml	Placebo 100mg/ml	Treated 100mg/ml
WOUND INDEX	0.0 \pm 0.0	7.86 \pm 0.33	8.93 \pm 0.14	3.86 \pm 0.37	8.96 \pm 0.29	1.43 \pm 0.12

4.5 ELISA VEGF

The graph data shows that the group of rats treated with lemon grass plant extract in comparison to injured groups shows a significant value of VEGF markers and results were estimated by applying one-way ANOVA using graph pad.




Figure 4.7: VEGF levels in treated groups of rats with selected doses of Lemon grass extracts increases as compared to injured groups of rats. Asterisk symbol *** indicates high significant in results ($P < 0.001$). The mean \pm SEM is used to express the values.

Table 4.3: Graphical results values of ELISA VEGF expressed in mean \pm SEM

	Normal	Injured	Placebo 50mg/ml	Treated 50mg/ml	Placebo 100mg/ml	Treated 100mg/ml
VEGF	2.46 \pm 0.04	1.66 \pm 0.07	1.65 \pm 0.08	2.37 \pm 0.03	1.62 \pm 0.08	2.63 \pm 0.12

4.6 ELISA Annexin V

The graph data shows that the group of rats treated with lemon grass plant extract in comparison to injured groups shows a significant increase of annexin marker and decreased apoptosis after treatment with lemon grass. The results were estimated by applying one-way ANOVA using graph pad.




Figure 4.8: Annexin V levels in treated group of rats with selected doses of Lemon grass extract decreased as compared to injured group of rats. *** indicates high significant in results ($P < 0.001$). The mean \pm SEM is used to express the values.

Table 4.4: Graphical results values of Annexin V expressed in mean \pm SEM

	Normal	Injured	Placebo 50mg/ml	Treated 50mg/ml	Placebo 100mg/ml	Treated 100mg/ml
ANNEXIN V	1.15 \pm 0.03	1.61 \pm 0.01	1.44 \pm 0.03	1.11 \pm 0.04	1.46 \pm 0.02	1.14 \pm 0.08

4.7 Antioxidant Analysis

4.7.1 Estimation of APOX

A biochemical test which is responsible for finding out the estimation of APOX level is Lemon grass.




Figure 4.9: APOX levels in treated group of rats with selected doses of Lemon grass powder in comparison to injured group of rats. *** indicates that there is high statistical significance in the results ($P < 0.001$). The mean \pm SEM is used to express the values.

Table 4.5: Graphical results values of APOX expressed in mean \pm SEM

	Normal	Injured	Placebo 50mg/ml	Treated 50mg/ml	Placebo 100mg/ml	Treated 100mg/ml
APOX	0.35 \pm 0.01	0.82 \pm 0.03	0.82 \pm 0.04	0.56 \pm 0.03	0.82 \pm 0.02	0.42 \pm 0.01

4.7.2 Estimation of SOD

A biochemical test which is responsible for finding out the estimation of SOD level is Lemon grass.




Figure 4.10: SOD levels in treated groups of rats with selected doses of Lemon grass extract in comparison to injured group of rats. *** Symbols indicate high significant in results ($P < 0.001$). The mean \pm SEM is used to express the values.

Table 4.6: Graphical results values of SOD expressed in mean \pm SEM

	Normal	Injured	Placebo 50mg/ml	Treated 50mg/ml	Placebo 100mg/ml	Treated 100mg/ml
SOD	11.72 \pm 0.09	17.81 \pm 0.20	17.74 \pm 0.30	16.41 \pm 0.55	17.81 \pm 0.31	12.94 \pm 0.19

4.7.3 Estimation of GSH

A biochemical test which is responsible for finding out the estimation of GSH level is Lemon grass.




Figure 4.11: GSH levels in treated groups of rats with selected doses of Lemon grass extract in comparison to injured group of rats. *** Symbols indicate high significant in results ($P < 0.001$). The mean \pm SEM is used to express the values.

Table 4.7: Graphical results values of GSH expressed in mean \pm SEM

	Normal	Injured	Placebo 50mg/ml	Treated 50mg/ml	Placebo 100mg/ml	Treated 100mg/ml
GSH	0.92 \pm 0.03	0.22 \pm 0.01	0.21 \pm 0.008	0.63 \pm 0.009	0.23 \pm 0.004	0.94 \pm 0.03

4.7.4 Estimation of CAT

A biochemical test which is responsible for finding out the estimation of CAT level is Lemon grass.




Figure 4.12: CAT levels in treated groups of rats with selected doses of Lemon grass extract in comparison to injured group of rats. *** Symbols indicate high significant in results ($P < 0.001$). The mean \pm SEM is used to express the values.

Table 4.8: Graphical results values of CAT expressed in mean \pm SEM

	Normal	Injured	Placebo 50mg/ml	Treated 50mg/ml	Placebo 100mg/ml	Treated 100mg/ml
CAT	0.93 \pm 0.02	0.33 \pm 0.002	0.32 \pm 0.01	0.60 \pm 0.008	0.33 \pm 0.01	0.91 \pm 0.03

4.8 Histopathology

4.8.1 Group 1: Normal group

Three layers of tissue make up the skin: Epidermis, Dermis, the middle layer and hypodermis, the fatty layer. The epidermis is composed of keratinized, stratified squamous epithelium. It is made of four or five layers of epithelial cells. The dermis, beneath the epidermis, contains tough connective tissue, hair follicles, and sweat glands. The above figure of normal group result shows the thickness of skin which means that histologically skin's glands are normal.



Figure 4.13: Histological Diagram of Normal Skin of Albino Rats

4.8.2 Group 2: Injury group

A burn wound's physiology is characterized by an inflammatory response that triggers the rapid formation of oedema due to increased microvascular sensitivity, vessel dilatability, and extravascular osmotic activity. The above figure shows the inflammation, skin thickness is compromised and the small dots in figure shows the inflammatory cells that are integrate in burn skin. The whole skin architecture is destroyed.




Figure 4.14: Histological Diagram of Injured Skin of Albino Rats

4.8.3 Group 3: Placebo 1

The physiology of a burn wound is distinct from other wound types because of the inflammatory response that causes extravascular osmotic activity, vessel dilatation, and enhanced microvascular sensitivity, which quickly generates oedema. In the image above, the damaged skin thickness can be seen together with the inflammatory cells that are incorporated into burn skin. The entire structure of the skin is damaged.




Figure 4.15: Histological Diagram (50mg/ml Normal Saline) Skin of Albino Rats

4.8.4 Group 4: Treated 1

The above result of histopathology of rat's skin treated with treatment 1 (50mg/kg plant aqueous extract) shows that the skin thickness is reconstructed. The entire structure of the skin is build.




Figure 4.16: Histological Diagram of Treated 1 Skin of Albino Rats

4.8.5 Group 5: Placebo 2

A burn wound's physiology is characterized by an inflammatory response that results in rapid oedema generation as a result of increased microvascular sensitivity, vessel dilation, and extravascular osmotic activity. Inflammatory cells that are integrated into burn skin are visible in the above image as small dots, and the skin thickness is destroyed. The top pink colour indicates inflammation. The whole structure of the skin is disrupted.




Figure 4.17: Histological Diagram (100 mg/ml Normal Saline) Skin of Albino Rats

4.8.6 Group 6: Treated 2

The above result of histopathology of rat's skin treated with treatment 2 (100mg/kg plant aqueous extract) shows that the skin thickness is reconstructed. The skin's overall structure gradually returns to normal.




Figure 4.18: Histological Diagram of Treated 2 skin of Albino Rats

CHAPTER 5

DISCUSSION

The Wound healing and Antifungal Properties of lemon grass was investigated by using estimation of antioxidants, wound index measurement, sandwich enzyme-linked immunosorbent assay, and histopathological testing at different doses of aqueous extract of lemon grass (107, 189). A burn wound's physiology is characterized by an inflammatory response that triggers the rapid formation of oedema due to increased microvascular sensitivity, vessel dilatability, and extravascular osmotic activity. One of the most significant proangiogenic mediators in wound healing is VEGF (190). The increase in VEGF following damage is likely due to multiple cellular sources. Damaged skin produces more VEGF, which is typically expressed at low levels by epidermal keratinocytes (8). The Sandwich Elisa results of ANNEXIN-V demonstrated that the level of apoptosis is decreased with treatment of plant extract of lemon grass. ANNEXIN-V is a marker for apoptosis (191).

The antifungal, anti-inflammatory, antioxidant, antibacterial, antifever, antifilarial, antidyspeptic, anti-amoebic, analgesic, antimicrobial, antiviral, antihypertensive, antihyperglycemic, antinociceptive, and wound healing properties of the lemon grass plant have been demonstrated in vitro and in vivo using plant materials (31). The Lemon grass plant's potential to heal wounds was proven by the wound index measurement. Wound index level was measured in treated group of rats with selected doses of lemon grass extract in comparison to injured group of rats. The symbol *** denotes high statistical significance in results ($P < 0.001$). The rat groups treated with the lemon grass plant extract had remarkable wound index (reduction) values, and results were assessed using one-way ANOVA in graph pad (29).

Estimates were made for the antioxidant assays, including APOX, GSH, CAT and SOD. By utilising one-way ANOVA in Graph Pad, the APOX levels, GSH levels, CAT levels, and SOD levels in the injured vs. treated group of rats with specific doses of lemon grass reveal that the results obtained were highly significant with p value < 0.001 . Antioxidants

are believed to facilitate the control of oxidative stress in the wound healing process (192).

The histopathology results of normal group of rats showed that the glands of the skin are normal. All the skin layers are present. The results of injured group of rats showed inflammation, skin thickness is compromised and inflammatory cells are formed that are integrated in burn skin. The whole skin structure is destroyed. Same damaged skin structures were showed in skins treated with placebo 1 (50mg/ml) and placebo 2 (100mg/ml). While the histopathology results of treated group of rats (50 and 100 mg/ml) showed that the skin thickness is reconstructed and the entire structure of the skin is gradually backed to normal.

All these results concluded that lemon grass has antifungal properties and wound healing potential and could be very effective in the treatment of skin wound injuries.

CONCLUSION

Lemon grass extracts showed potential antifungal and wound healing properties. The antifungal testing of lemon grass extracts on *Candida albicans* proved the antifungal potential of lemon grass extracts. At high and low doses of lemon grass extracts, it demonstrated remarkable antifungal ability by showing the inhibition zone. The wound healing ability of lemon grass extracts was confirmed using wound index measurement, antioxidant estimation, sandwich enzyme-linked immunosorbent assay (ELISA) protocol, and histopathological test. Lemon grass extract confirmed greatest wound healing potential by increases the vascular endothelial growth factor (VEGF) at various doses (50 and 100 mg/ml). The results obtained were highly significant. At high dose of lemon grass extracts, it demonstrated remarkable wound healing potential, whereas at low dose, it also demonstrated good results. The confirmation of antifungal and wound healing properties of lemon grass extracts open a new horizon for future research to treat acid burn injuries and wound treatments.

REFERENCES

1. Guo Sa, DiPietro LA. Factors affecting wound healing. *Journal of dental research*. 2010;89(3):219-29.
2. Tonnesen MG, Feng X, Clark RA, editors. *Angiogenesis in wound healing*. *Journal of Investigative Dermatology Symposium Proceedings*; 2000: Elsevier.
3. George Broughton I, Janis JE, Attinger CE. The basic science of wound healing. *Plastic and reconstructive surgery*. 2006;117(7S):12S-34S.
4. DiPietro LA. Angiogenesis and wound repair: when enough is enough. *Journal of leukocyte biology*. 2016;100(5):979-84.
5. Adair TH, Montani J-P, editors. *Angiogenesis*. *Colloquium series on integrated systems physiology: from molecule to function*; 2010: Morgan & Claypool Life Sciences.
6. Veith AP, Henderson K, Spencer A, Sligar AD, Baker AB. Therapeutic strategies for enhancing angiogenesis in wound healing. *Advanced drug delivery reviews*. 2019;146:97-125.
7. Honnegowda TM, Kumar P, Udupa EGP, Kumar S, Kumar U, Rao P. Role of angiogenesis and angiogenic factors in acute and chronic wound healing. *Plastic and Aesthetic Research*. 2015;2:243-9.
8. Bao P, Kodra A, Tomic-Canic M, Golinko MS, Ehrlich HP, Brem H. The role of vascular endothelial growth factor in wound healing. *Journal of Surgical Research*. 2009;153(2):347-58.
9. Berra E, Pouyssegur J. MAP kinases and hypoxia in the control of VEGF expression. *Cancer and Metastasis reviews*. 2000;19(1):139-45.
10. Rossiter H, Barresi C, Pammer J, Rendl M, Haigh J, Wagner EF, et al. Loss of vascular endothelial growth factor activity in murine epidermal keratinocytes delays wound healing and inhibits tumor formation. *Cancer research*. 2004;64(10):3508-16.
11. Bauer SM, Bauer RJ, Velazquez OC. Angiogenesis, vasculogenesis, and induction of healing in chronic wounds. *Vascular and endovascular surgery*. 2005;39(4):293-306.

12. Carmeliet P. Angiogenesis in life, disease and medicine. *Nature*. 2005;438(7070):932-6.
13. Dvorak H. Angiogenesis: update 2005. *Journal of Thrombosis and Haemostasis*. 2005;3(8):1835-42.
14. Lancerotto L, Orgill DP. Mechanoregulation of angiogenesis in wound healing. *Advances in wound care*. 2014;3(10):626-34.
15. Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. *Nature medicine*. 2003;9(6):669-76.
16. Joško J, Gwóźdź B, Jedrzejowska-Szypułka H, Hendryk S. Vascular endothelial growth factor (VEGF) and its effect on angiogenesis. *Medical science monitor: international medical journal of experimental and clinical research*. 2000;6(5):1047-52.
17. Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. *Mechanisms of angiogenesis*. 2005:209-31.
18. Johnson KE, Wilgus TA. Vascular endothelial growth factor and angiogenesis in the regulation of cutaneous wound repair. *Advances in wound care*. 2014;3(10):647-61.
19. Skaria BP, Joy P, Mathew S, Mathew G. Lemongrass. *Handbook of herbs and spices*: Elsevier; 2006. p. 400-19.
20. Avila-Sosa R, Palou E, Munguía MTJ, Nevárez-Moorillón GV, Cruz ARN, López-Malo A. Antifungal activity by vapor contact of essential oils added to amaranth, chitosan, or starch edible films. *International journal of food microbiology*. 2012;153(1-2):66-72.
21. Olorunnisola S, Asiyambi H, Hamed A, Simsek S. Biological properties of lemongrass: An overview. *International Food Research Journal*. 2014;21(2):455.
22. Joy P, Skaria BP, Mathew S, Mathew G, Joseph A, Sreevidya P. Lemongrass. In: *J Arecanut Spices Medicin Plants*. 2006;2:55-64.
23. Sharma S, Habib S, Sahu D, Gupta J. Chemical properties and therapeutic potential of citral, a monoterpene isolated from lemongrass. *Medicinal Chemistry*. 2021;17(1):2-12.
24. Kamaruddin ZH, Jumaidin R, Selamat MZ, Ilyas R. Characteristics and Properties of Lemongrass (*Cymbopogon Citratus*): A Comprehensive Review. *Journal of Natural Fibers*. 2021:1-18.

25. Shah G, Shri R, Panchal V, Sharma N, Singh B, Mann A. Scientific basis for the therapeutic use of *Cymbopogon citratus*, stapf (Lemon grass). *Journal of advanced pharmaceutical technology & research*. 2011;2(1):3.
26. Oboh G, Adefegha S, Ademosun A, Unu D. Effects of hot water treatment on the phenolic phytochemicals and antioxidant activities of lemon grass (*Cymbopogon citratus*). *Electronic Journal of Environmental, Agricultural & Food Chemistry*. 2010;9(3).
27. Tzortzakis NG, Economakis CD. Antifungal activity of lemongrass (*Cymbopogon citratus* L.) essential oil against key postharvest pathogens. *Innovative Food Science & Emerging Technologies*. 2007;8(2):253-8.
28. Mickiene R, Bakutis B, Baliukoniene V. Antimicrobial activity of two essential oils. *Annals of Agricultural and Environmental Medicine*. 2011;18(1).
29. Thangapazham RL, Sharad S, Maheshwari RK. Phytochemicals in wound healing. *Advances in wound care*. 2016;5(5):230-41.
30. Silva CdBd, Guterres SS, Weisheimer V, Schapoval EE. Antifungal activity of the lemongrass oil and citral against *Candida* spp. *Brazilian Journal of Infectious Diseases*. 2008;12:63-6.
31. Olorunnisola S, Hammed A, Simsek S. Biological properties of lemongrass: An overview. *International Food Research Journal*. 2014;21(2).
32. Laut M, Ndaong N, Utami T, editors. Cutaneous wound healing activity of herbal ointment containing the leaf extract of *Acalypha indica* L. on mice (*Mus musculus*). *Journal of Physics: Conference Series*; 2019: IOP Publishing.
33. Bowler P, Duerden B, Armstrong DG. Wound microbiology and associated approaches to wound management. *Clinical microbiology reviews*. 2001;14(2):244-69.
34. Hunt TK, Hopf H, Hussain Z. Physiology of wound healing. *Advances in skin & wound care*. 2000;13:6.
35. Han G, Ceilley R. Chronic wound healing: a review of current management and treatments. *Advances in therapy*. 2017;34(3):599-610.
36. Monaco JL, Lawrence WT. Acute wound healing: an overview. *Clinics in plastic surgery*. 2003;30(1):1-12.

37. Yamaguchi Y, Yoshikawa K. Cutaneous wound healing: an update. *The Journal of dermatology*. 2001;28(10):521-34.
38. Hosgood G. Stages of wound healing and their clinical relevance. *Veterinary Clinics: Small Animal Practice*. 2006;36(4):667-85.
39. Androutsos G, Vladimirov L, Diamantis A. John Hunter (1728-1793): founder of scientific surgery and precursor of oncology. *Journal of BU ON: Official Journal of the Balkan Union of Oncology*. 2007;12(3):421-7.
40. Natale G, Bocci G, Lenzi P. Looking for the word “Angiogenesis” in the history of health sciences: from ancient times to the first decades of the twentieth century. *World journal of surgery*. 2017;41(6):1625-34.
41. Patan S. Vasculogenesis and angiogenesis as mechanisms of vascular network formation, growth and remodeling. *Journal of neuro-oncology*. 2000;50(1):1-15.
42. Patan S. Vasculogenesis and angiogenesis. *Angiogenesis in brain tumors*. 2004:3-32.
43. Ribatti D, Crivellato E. “Sprouting angiogenesis”, a reappraisal. *Developmental biology*. 2012;372(2):157-65.
44. Bonanno E, Iurlaro M, Madri JA, Nicosia RF. Type IV collagen modulates angiogenesis and neovessel survival in the rat aorta model. *In Vitro Cellular & Developmental Biology-Animal*. 2000;36(5):336-40.
45. Folkman J. Angiogenesis. *Biology of endothelial cells*. 1984:412-28.
46. Folkman J. Tumor angiogenesis: therapeutic implications. *New England Journal of Medicine*. 1971;285(21):1182-6.
47. Polverini PJ, Cotran RS, Gimbrone MA, Unanue ER. Activated macrophages induce vascular proliferation. *Nature*. 1977;269(5631):804-6.
48. Castellot JJ, Karnovsky MJ, Spiegelman BM. Differentiation-dependent stimulation of neovascularization and endothelial cell chemotaxis by 3T3 adipocytes. *Proceedings of the National Academy of Sciences*. 1982;79(18):5597-601.
49. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. *Nature*. 1992;359(6398):843-5.

50. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'shea KS, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. *Nature*. 1996;380(6573):439-42.
51. Dvorak H, Nagy J, Feng D, Brown L, Dvorak A. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. *Vascular growth factors and angiogenesis*. 1999:97-132.
52. Brown L, Detmar M, Claffey K, Nagy J, Feng D, Dvorak A, et al. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. *Regulation of angiogenesis*. 1997:233-69.
53. Carmeliet P, Collen D. Role of vascular endothelial growth factor and vascular endothelial growth factor receptors in vascular development. *Vascular growth factors and angiogenesis*. 1999:133-58.
54. Ferrara N, editor *Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications*. *Seminars in oncology*; 2002: Elsevier.
55. Carmeliet P. Blood vessels and nerves: common signals, pathways and diseases. *Nature Reviews Genetics*. 2003;4(9):710-20.
56. Mukoyama Y-s, Shin D, Britsch S, Taniguchi M, Anderson DJ. Sensory nerves determine the pattern of arterial differentiation and blood vessel branching in the skin. *Cell*. 2002;109(6):693-705.
57. Honma Y, Araki T, Gianino S, Bruce A, Heuckeroth RO, Johnson Jr EM, et al. Artemin is a vascular-derived neurotropic factor for developing sympathetic neurons. *Neuron*. 2002;35(2):267-82.
58. Park KW, Crouse D, Lee M, Karnik SK, Sorensen LK, Murphy KJ, et al. The axonal attractant Netrin-1 is an angiogenic factor. *Proceedings of the National Academy of Sciences*. 2004;101(46):16210-5.
59. Basu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA, Susan Bliss V, et al. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. *Nature medicine*. 2001;7(5):569-74.

60. Dvorak H, Rickles F. Malignancy and hemostasis. Hemostasis and Thrombosis: Basic Principles and Clinical Practice Philadelphia: Lippincott Company Williams & Wilkins. 2006;851:73.
61. Zhang Y, Deng Y, Luther T, Müller M, Ziegler R, Waldherr R, et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. The Journal of clinical investigation. 1994;94(3):1320-7.
62. Abe K, Shoji M, Chen J, Bierhaus A, Danave I, Micko C, et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proceedings of the National Academy of Sciences. 1999;96(15):8663-8.
63. Clauss M, Gerlach M, Gerlach H, Brett J, Wang F, Familletti P, et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. The Journal of experimental medicine. 1990;172(6):1535-45.
64. Fernandez PM, Patierno SR, Rickles FR, editors. Tissue factor and fibrin in tumor angiogenesis. Seminars in thrombosis and hemostasis; 2004: Copyright© 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New
65. Tsopanoglou NE, Maragoudakis ME, editors. Role of thrombin in angiogenesis and tumor progression. Seminars in thrombosis and hemostasis; 2004: Copyright© 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New
66. Oh CW, Hoover-Plow J, Plow E. The role of plasminogen in angiogenesis in vivo. Journal of Thrombosis and Haemostasis. 2003;1(8):1683-7.
67. Browder T, Folkman J, Pirie-Shepherd S. The hemostatic system as a regulator of angiogenesis. Journal of Biological Chemistry. 2000;275(3):1521-4.
68. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Annals of surgery. 1972;175(3):409.
69. Folkman J. Clinical applications of research on angiogenesis. New England Journal of Medicine. 1995;333(26):1757-63.
70. Crovetti G, Martinelli G, Issi M, Barone M, Guizzardi M, Campanati B, et al. Platelet gel for healing cutaneous chronic wounds. Transfusion and Apheresis Science. 2004;30(2):145-51.

71. Falanga V. The chronic wound: impaired healing and solutions in the context of wound bed preparation. *Blood Cells, Molecules, and Diseases*. 2004;32(1):88-94.
72. Shiota N, Nishikori Y, Kakizoe E, Shimoura K, Niibayashi T, Shimbori C, et al. Pathophysiological role of skin mast cells in wound healing after scald injury: study with mast cell-deficient W/W^v mice. *International archives of allergy and immunology*. 2010;151(1):80-8.
73. Song X, Luo Y. The regulatory mechanism of Hsp90 α secretion from endothelial cells and its role in angiogenesis during wound healing. *Biochemical and biophysical research communications*. 2010;398(1):111-7.
74. Arnold F, West DC. Angiogenesis in wound healing. *Pharmacology & therapeutics*. 1991;52(3):407-22.
75. Flegg JA, Byrne HM, Flegg MB, McElwain DS. Wound healing angiogenesis: the clinical implications of a simple mathematical model. *Journal of theoretical biology*. 2012;300:309-16.
76. Guerra A, Belinha J, Jorge RN. Modelling skin wound healing angiogenesis: A review. *Journal of theoretical biology*. 2018;459:1-17.
77. Eming SA, Brachvogel B, Odorisio T, Koch M. Regulation of angiogenesis: wound healing as a model. *Progress in histochemistry and cytochemistry*. 2007;42(3):115-70.
78. DiPietro LA. Angiogenesis and scar formation in healing wounds. *Current opinion in rheumatology*. 2013;25(1):87-91.
79. Banda MJ, Knighton DR, Hunt TK, Werb Z. Isolation of a nonmitogenic angiogenesis factor from wound fluid. *Proceedings of the National Academy of Sciences*. 1982;79(24):7773-7.
80. Nissen NN, Polverini P, Koch AE, Volin MV, Gamelli RL, DiPietro LA. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. *The American journal of pathology*. 1998;152(6):1445.
81. Wietecha MS, Król MJ, Michalczyk ER, Chen L, Gettins PG, DiPietro LA. Pigment epithelium-derived factor as a multifunctional regulator of wound healing. *American Journal of Physiology-Heart and Circulatory Physiology*. 2015;309(5):H812-H26.

82. Lange-Asschenfeldt B, Velasco P, Streit M, Hawighorst T, Detmar M, Pike SE, et al. The angiogenesis inhibitor vasostatin does not impair wound healing at tumor-inhibiting doses. *Journal of investigative dermatology*. 2001;117(5):1036-41.
83. Berger AC, Feldman AL, Gnant MF, Kruger EA, Sim BKL, Hewitt S, et al. The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing. *Journal of Surgical Research*. 2000;91(1):26-31.
84. Roman CD, Choy H, Nanney L, Riordan C, Parman K, Johnson D, et al. Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats. *Journal of Surgical Research*. 2002;105(1):43-7.
85. Wilgus TA, Ferreira AM, Oberyshyn TM, Bergdall VK, DiPietro LA. Regulation of scar formation by vascular endothelial growth factor. *Laboratory investigation*. 2008;88(6):579-90.
86. Diao J-S, Xia W-S, Guo S-Z. Bevacizumab: a potential agent for prevention and treatment of hypertrophic scar. *Burns: Journal of the International Society for Burn Injuries*. 2010;36(7):1136-7.
87. Ren H-t, Hu H, Li Y, Jiang H-f, Hu X-l, Han C-m. Endostatin inhibits hypertrophic scarring in a rabbit ear model. *Journal of Zhejiang University SCIENCE B*. 2013;14(3):224-30.
88. Gira AK, Brown LF, Washington CV, Cohen C, Arbiser JL. Keloids demonstrate high-level epidermal expression of vascular endothelial growth factor. *Journal of the American Academy of Dermatology*. 2004;50(6):850-3.
89. Amadeu T, Braune A, Mandarin-de-Lacerda C, Porto LC, Desmoulière A, Costa A. Vascularization pattern in hypertrophic scars and keloids: a stereological analysis. *Pathology-Research and Practice*. 2003;199(7):469-73.
90. van der Veer WM, Niessen FB, Ferreira JA, Zwiers PJ, de Jong EH, Middelkoop E, et al. Time course of the angiogenic response during normotrophic and hypertrophic scar formation in humans. *Wound Repair and Regeneration*. 2011;19(3):292-301.
91. Farkas L, Gauldie J, Voelkel NF, Kolb M. Pulmonary hypertension and idiopathic pulmonary fibrosis: a tale of angiogenesis, apoptosis, and growth factors. *American journal of respiratory cell and molecular biology*. 2011;45(1):1-15.

92. Elpek GÖ. Angiogenesis and liver fibrosis. *World journal of hepatology*. 2015;7(3):377.
93. Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. *Nature*. 2008;453(7193):314-21.
94. Singer AJ, Clark RA. Cutaneous wound healing. *New England journal of medicine*. 1999;341(10):738-46.
95. Cebe-Suarez S, Zehnder-Fjällman A, Ballmer-Hofer K. The role of VEGF receptors in angiogenesis; complex partnerships. *Cellular and molecular life sciences*. 2006;63(5):601-15.
96. Dvorak HF, editor VPF/VEGF and the angiogenic response. *Seminars in perinatology*; 2000: Elsevier.
97. Sia D, Alsinet C, Newell P, Villanueva A. VEGF signaling in cancer treatment. *Current pharmaceutical design*. 2014;20(17):2834-42.
98. Brown LF, Yeo K, Berse B, Yeo T-K, Senger DR, Dvorak HF, et al. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. *The Journal of experimental medicine*. 1992;176(5):1375-9.
99. Kishimoto J, Ehama R, Ge Y, Kobayashi T, Nishiyama T, Detmar M, et al. In vivo detection of human vascular endothelial growth factor promoter activity in transgenic mouse skin. *The American journal of pathology*. 2000;157(1):103-10.
100. Willenborg S, Lucas T, Van Loo G, Knipper JA, Krieg T, Haase I, et al. CCR2 recruits an inflammatory macrophage subpopulation critical for angiogenesis in tissue repair. *Blood, The Journal of the American Society of Hematology*. 2012;120(3):613-25.
101. Corral CJ, Siddiqui A, Wu L, Farrell CL, Lyons D, Mustoe TA. Vascular endothelial growth factor is more important than basic fibroblastic growth factor during ischemic wound healing. *Archives of surgery*. 1999;134(2):200-5.
102. Ranade SS, Thiagarajan P. Lemon grass. *Int J Pharm Sci Rev Res*. 2015;35(2):162-7.
103. Ravinder K, Pawan K, Gaurav S, Paramjot K, Gagan S, Appramdeep K. Pharmacognostical investigation of *Cymbopogon citratus* (DC) Stapf. *Scholars Research Library*. 2010;2:181-9.

104. Tajidin N, Ahmad S, Rosenani A, Azimah H, Munirah M. Chemical composition and citral content in lemongrass (*Cymbopogon citratus*) essential oil at three maturity stages. *African Journal of Biotechnology*. 2012;11(11):2685.
105. Manvitha K, Bidya B. Review on pharmacological activity of *Cymbopogon citratus*. *International Journal of herbal medicine*. 2014;1(6):07-.
106. Ramesh B, Indi S, Rao K. Anti-amyloidogenic property of leaf aqueous extract of *Caesalpinia crista*. *Neuroscience letters*. 2010;475(2):110-4.
107. Abdulazeez MA, Abdullahi AS, James BD. Lemongrass (*Cymbopogon* spp.) oils. *Essential oils in food preservation, flavor and safety*: Elsevier; 2016. p. 509-16.
108. Negrelle R, Gomes E. *Cymbopogon citratus* (DC.) Stapf: chemical composition and biological activities. *Revista Brasileira de Plantas Medicinai*s. 2007;9(1):80-92.
109. Souza F, Lodder H, Gianotti F. O., Ferreira, T. M. and Carlini, TA 1986. Pharmacology of Lemon grass (*Cymbopogon citratus* Stapf.). II. Effects of daily two month administration in male and female rats and in offspring exposed “in utero”. *Journal of Ethnopharmacology*.17:65-74.
110. Filipov A. Medicinal plants of the Pilagá of Central Chaco. *Journal of Ethnopharmacology*. 1994;44(3):181-93.
111. Ekpenyong CE, Akpan E, Nyoh A. Ethnopharmacology, phytochemistry, and biological activities of *Cymbopogon citratus* (DC.) Stapf extracts. *Chinese journal of natural medicines*. 2015;13(5):321-37.
112. Mirghani M, Liyana Y, Parveen J. Bioactivity analysis of lemongrass (*Cymbopogon citratus*) essential oil. 2012.
113. Ojo O, Kabutu F, Bello M, Babayo U. Inhibition of paracetamol-induced oxidative stress in rats by extracts of lemongrass (*Cymbopogon citratus*) and green tea (*Camellia sinensis*) in rats. *African Journal of Biotechnology*. 2006;5(12).
114. Karbach J, Ebenezer S, Warnke P, Behrens E, Al-Nawas B. Antimicrobial effect of Australian antibacterial essential oils as alternative to common antiseptic solutions against clinically relevant oral pathogens. *Clin Lab*. 2015;61(1-2):61-8.
115. Alfa I, Dahunsi S, Iorhemen O, Okafor C, Ajayi S. Comparative evaluation of biogas production from Poultry droppings, Cow dung and Lemon grass. *Bioresource technology*. 2014;157:270-7.

116. Babarinde A, Ogundipe K, Sangosanya KT, Akintola BD, Hassan A-OE. Comparative study on the biosorption of Pb (II), Cd (II) and Zn (II) using Lemon grass (*Cymbopogon citratus*): kinetics, isotherms and thermodynamics. *Chem Int.* 2016;2(8):89-102.
117. Firdaus MYN, Osman H, Metselaar HS, Rozyanty AR. A simple method for the production of pure crystalline silica from lemon grass. *BioResources.* 2016;11(1):1270-9.
118. Kaur H, Dutt D. Anatomical, morphological and chemical characterization of lignocellulosic by-products of lemon and sofia grasses obtained after recuperation of essential oils by steam distillation. *Cellulose Chemistry and Technology.* 2013;47(1-2):83-94.
119. Bekele LD, Zhang W, Liu Y, Duns GJ, Yu C, Jin L, et al. Preparation and characterization of lemongrass fiber (*Cymbopogon* species) for reinforcing application in thermoplastic composites. *BioResources.* 2017;12(3):5664-81.
120. YANG D-m, SU W-q, YUE J-q. Teaching Reform and Practice on Plant Fiber Chemistry. *Heilongjiang Pulp & Paper.* 2015.
121. Bajpai P. Pretreatment of lignocellulosic biomass. *Pretreatment of lignocellulosic biomass for Biofuel Production: Springer;* 2016. p. 17-70.
122. Pierson Y, Bobbink F, Yan N. Alcohol mediated liquefaction of lignocellulosic materials: a mini review. *Chem Eng Process Tech.* 2013;1(2):1014.
123. Carlson LHC, Machado RAF, Spricigo CB, Pereira LK, Bolzan A. Extraction of lemongrass essential oil with dense carbon dioxide. *The Journal of Supercritical Fluids.* 2001;21(1):33-9.
124. Hanaa AM, Sallam Y, El-Leithy A, Aly SE. Lemongrass (*Cymbopogon citratus*) essential oil as affected by drying methods. *Annals of Agricultural Sciences.* 2012;57(2):113-6.
125. Rauber CdS, Guterres SS, Schapoval EE. LC determination of citral in *Cymbopogon citratus* volatile oil. *Journal of Pharmaceutical and Biomedical Analysis.* 2005;37(3):597-601.
126. Moore-Neibel K, Gerber C, Patel J, Friedman M, Ravishankar S. Antimicrobial activity of lemongrass oil against *Salmonella enterica* on organic leafy greens. *Journal of Applied Microbiology.* 2012;112(3):485-92.

127. Evans WC. Trease and Evans' pharmacognosy: Elsevier Health Sciences; 2009.
128. Mian KH, Mohamed S. Flavonoid (myricetin, quercetin, kaempferol, luteolin, and apigenin) content of edible tropical plants. *Journal of agricultural and food chemistry*. 2001;49(6):3106-12.
129. Akhila A. Essential oil-bearing grasses: the genus *Cymbopogon*: CRC press; 2009.
130. Cheel J, Theoduloz C, Rodríguez J, Schmeda-Hirschmann G. Free radical scavengers and antioxidants from Lemongrass (*Cymbopogon citratus* (DC.) Stapf.). *Journal of agricultural and food chemistry*. 2005;53(7):2511-7.
131. Bharti S, Kumar A, Prakash O, Krishnan S, Gupta A. Essential oil of *Cymbopogon Citratus* against diabetes: Validation by. *vivo*; 2013.
132. Saleem M, Afza N, Anwar MA, Hai SMA, Ali MS, Shujaat S, et al. Chemistry and biological significance of essential oils of *Cymbopogon citratus* from Pakistan. *Natural Product Research*. 2003;17(3):159-63.
133. Saleem M, Afza N, Anwar MA, Hai SMA, Ali MS. A comparative study of essential oils of *Cymbopogon citratus* and some members of the genus *Citrus*. *Natural Product Research*. 2003;17(5):369-73.
134. Aftab K, Ali M, Aijaz P, Beena N, Gulzar H, Sheikh K, et al. Determination of different trace and essential element in lemon grass samples by x-ray fluorescence spectroscopy technique. *International food research journal*. 2011;18(1).
135. Haque ANMA, Remadevi R, Naebe M. Lemongrass (*Cymbopogon*): a review on its structure, properties, applications and recent developments. *Cellulose*. 2018;25(10):5455-77.
136. Tchoumboungang F, Zollo PA, Dagne E, Mekonnen Y. In vivo antimalarial activity of essential oils from *Cymbopogon citratus* and *Ocimum gratissimum* on mice infected with *Plasmodium berghei*. *Planta medica*. 2005;71(01):20-3.
137. Pedroso RB, Ueda-Nakamura T, Filho BPD, Cortez DAG, Cortez LER, Morgado-Diaz JA, et al. Biological activities of essential oil obtained from *Cymbopogon citratus* on *Crithidia deanei*. *Acta Protozoologica*. 2007;45(3):231.
138. Bassolé I, Lamien-Meda A, Bayala B, Obame L, Ilboudo A, Franz C, et al. Chemical composition and antimicrobial activity of *Cymbopogon citratus* and

Cymbopogon giganteus essential oils alone and in combination. *Phytomedicine*. 2011;18(12):1070-4.

139. Revathi K, Kumar C, Thamizhavahan K. Combined antimicrobial activity of lemon grass oil and Tulasi oil. *Int J Preclinical Pharm Res*. 2012;3(2):79-81.

140. Azeredo CM, Soares MJ. Combination of the essential oil constituents citral, eugenol and thymol enhance their inhibitory effect on *Crithidia fasciculata* and *Trypanosoma cruzi* growth. *Revista Brasileira de Farmacognosia*. 2013;23(5):762-8.

141. Tadtong S, Watthanachaiyingcharoen R, Kamkaen N. Antimicrobial constituents and synergism effect of the essential oils from *Cymbopogon citratus* and *Alpinia galanga*. *Natural product communications*. 2014;9(2):1934578X1400900237.

142. Gilling DH, Kitajima M, Torrey JR, Bright KR. Mechanisms of antiviral action of plant antimicrobials against murine norovirus. *Applied and environmental microbiology*. 2014;80(16):4898-910.

143. Trindade LA, de Araújo Oliveira J, de Castro RD, de Oliveira Lima E. Inhibition of adherence of *C. albicans* to dental implants and cover screws by *Cymbopogon nardus* essential oil and citronellal. *Clinical oral investigations*. 2015;19(9):2223-31.

144. Viana G, Vale T, Pinho R, Matos F. Antinociceptive effect of the essential oil from *Cymbopogon citratus* in mice. *Journal of Ethnopharmacology*. 2000;70(3):323-7.

145. Wannissorn B, Jarikasem S, Siriwangchai T, Thubthimthed S. Antibacterial properties of essential oils from Thai medicinal plants. *Fitoterapia*. 2005;76(2):233-6.

146. Boukhatem MN, Ferhat MA, Kameli A, Saidi F, Kebir HT. Lemon grass (*Cymbopogon citratus*) essential oil as a potent anti-inflammatory and antifungal drugs. *Libyan Journal of Medicine*. 2014;9(1).

147. Pattnaik S, Subramanyam VR, Bapaji M, Kole CR. Antibacterial and antifungal activity of aromatic constituents of essential oils. *Microbios*. 1997;89(358):39-46.

148. Hindumathy C. In vitro antibacterial activity of lemongrass [J]. *ISSRI*. 2011;5(2):164-8.

149. Suaeyun R, Kinouchi T, Arimochi H, Vinitketkumnuen U, Ohnishi Y. Inhibitory effects of lemon grass (*Cymbopogon citratus* Stapf) on formation of azoxymethane-induced DNA adducts and aberrant crypt foci in the rat colon. *Carcinogenesis*. 1997;18(5):949-55.

150. Vinitketkumnuen U, Puatanachokchai R, Kongtawelert P, Lertprasertsuke N, Matsushima T. Antimutagenicity of lemon grass (*Cymbopogon citratus* Stapf) to various known mutagens in salmonella mutation assay. *Mutation Research/Genetic Toxicology*. 1994;341(1):71-5.
151. De Blasi V, Debrot S, Menoud P, Gendre L, Schowing J. Amoebicidal effect of essential oils in vitro. *Journal de toxicologie clinique et expérimentale*. 1990;10(6):361-73.
152. Tangpu V, Yadav AK. Antidiarrhoeal activity of *Cymbopogon citratus* and its main constituent, citral. *Pharmacologyonline*. 2006;2:290-8.
153. Suresh M, Raj RK. Cardol: the antifilarial principle from *Anacardium occidentale*. *Current Science*. 1990:477-9.
154. Chungsamarnyart N, Jiwajinda S. Acaricidal activity of volatile oil from lemon and citronella grasses on tropical cattle ticks. *Kasetsart Journal*. 1992;26(5):46-51.
155. Dubey N, Tripathi P, Singh H. Prospects of some essential oils as antifungal agents. *Journal of Medicinal and Aromatic Plant Sciences*. 2000;22(1):350-4.
156. Nambiar VS, Matela H. Potential functions of lemon grass (*Cymbopogon citratus*) in health and disease. *International Journal of Pharmaceutical and Biological Archives*. 2012;3(5):1035-43.
157. Patel V, Metha B. Evaluation of Antioxidants in Lemon Grass and optimization of herbal tea formulae using Lemon Grass. M Sc Sardar Patel University: Vallabh Vidyanagar. 2006.
158. Francisco V, Figueirinha A, Neves BM, García-Rodríguez C, Lopes MC, Cruz MT, et al. *Cymbopogon citratus* as source of new and safe anti-inflammatory drugs: bio-guided assay using lipopolysaccharide-stimulated macrophages. *Journal of Ethnopharmacology*. 2011;133(2):818-27.
159. Tyagi AK, Gottardi D, Malik A, Guerzoni ME. Chemical composition, in vitro anti-yeast activity and fruit juice preservation potential of lemon grass oil. *LWT-Food Science and Technology*. 2014;57(2):731-7.
160. Silva CdBd, Guterres SS, Weisheimer V, Schapoval EE. Antifungal activity of the lemongrass oil and citral against *Candida* spp. *Brazilian Journal of Infectious Diseases*. 2008;12(1):63-6.

161. Inouye S, Uchida K, Yamaguchi H. In-vitro and in-vivo anti-Trichophyton activity of essential oils by vapour contact. *Mycoses*. 2001;44(3-4):99-107.
162. Abe S. Anti-Candida albicans activity of essential preparation including lemongrass (*Cymbopogon citratus*) preparation and its component, citral. *Jpn J Med Mycol*. 2003;44:285-91.
163. Onawunmi GO, Yisak W-A, Ogunlana E. Antibacterial constituents in the essential oil of *Cymbopogon citratus* (DC.) Stapf. *Journal of Ethnopharmacology*. 1984;12(3):279-86.
164. Melo SdF, Soares SF, da Costa RF, da Silva CR, de Oliveira MB, Bezerra RJ, et al. Effect of the *Cymbopogon citratus*, *Maytenus ilicifolia* and *Baccharis genistelloides* extracts against the stannous chloride oxidative damage in *Escherichia coli*. *Mutation research/genetic toxicology and environmental mutagenesis*. 2001;496(1-2):33-8.
165. Orafidiya LO. The effect of autoxidation of lemon-grass oil on its antibacterial activity. *Phytotherapy Research*. 1993;7(3):269-71.
166. Nguéfack J, Budde BB, Jakobsen M. Five essential oils from aromatic plants of Cameroon: their antibacterial activity and ability to permeabilize the cytoplasmic membrane of *Listeria innocua* examined by flow cytometry. *Letters in applied microbiology*. 2004;39(5):395-400.
167. Pereira RS, Sumita TC, Furlan MR, Jorge AOC, Ueno M. Antibacterial activity of essential oils on microorganisms isolated from urinary tract infection. *Revista de Saude Publica*. 2004;38:326-8.
168. Wannissorn B, Jarikasem S, Soontorntanasart T. Antifungal activity of lemon grass oil and lemon grass oil cream. *Phytotherapy Research*. 1996;10(7):551-4.
169. Kishore N, Mishra A, Chansouria J. Fungitoxicity of essential oils against dermatophytes: Die Fungitoxizität ätherischer Öle gegen Dermatophyten. *Mycoses*. 1993;36(5-6):211-5.
170. Abe S, Sato Y, Inoue S, Ishibashi H, Maruyama N, Takizawa T, et al. Anti-Candida albicans activity of essential oils including Lemongrass (*Cymbopogon citratus*) oil and its component, citral. *Nippon Ishinkin Gakkai Zasshi*. 2003;44(4):285-91.

171. Mishra A, Dubey N. Evaluation of some essential oils for their toxicity against fungi causing deterioration of stored food commodities. *Applied and environmental microbiology*. 1994;60(4):1101-5.
172. Arvill R. *Man and environment: crisis and the strategy of choice*: Penguin Books; 1970.
173. Pimsaeng K. Anti-micronucleus formation of lemon grass extract. Master's thesis, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. 1993.
174. Puatanachokchai R. Antimutagenicity, cytotoxicity and antitumor activity from lemon grass (*Cymbopogon citratus*, Stapf) extract. Graduate School thesis Chiang Mai University, Thailand. 1994:27-30.
175. Puatanachokchai R, Kishida H, Denda A, Murata N, Konishi Y, Vinitketkumnuen U, et al. Inhibitory effects of lemon grass (*Cymbopogon citratus*, Stapf) extract on the early phase of hepatocarcinogenesis after initiation with diethylnitrosamine in male Fischer 344 rats. *Cancer letters*. 2002;183(1):9-15.
176. Sharma PR, Mondhe DM, Muthiah S, Pal HC, Shahi AK, Saxena AK, et al. Anticancer activity of an essential oil from *Cymbopogon flexuosus*. *Chemico-biological interactions*. 2009;179(2-3):160-8.
177. Tiwari M, Dwivedi U, Kakkar P. Suppression of oxidative stress and pro-inflammatory mediators by *Cymbopogon citratus* D. Stapf extract in lipopolysaccharide stimulated murine alveolar macrophages. *Food and Chemical Toxicology*. 2010;48(10):2913-9.
178. Costa CA, Bidinotto LT, Takahira RK, Salvadori DM, Barbisan LF, Costa M. Cholesterol reduction and lack of genotoxic or toxic effects in mice after repeated 21-day oral intake of lemongrass (*Cymbopogon citratus*) essential oil. *Food and Chemical Toxicology*. 2011;49(9):2268-72.
179. Agbafor K, Akubugwo E. Hypocholesterolaemic effect of ethanolic extract of fresh leaves of *Cymbopogon citratus* (lemongrass). *African Journal of Biotechnology*. 2007;6(5):596-8.
180. Sousa SM, Silva PS, Viccini LF. Cytogenotoxicity of *Cymbopogon citratus* (DC) Stapf (lemon grass) aqueous extracts in vegetal test systems. *Anais da Academia Brasileira de Ciências*. 2010;82:305-11.


181. Treco DA, Lundblad V. Preparation of yeast media. *Current protocols in molecular biology*. 1993;23(1):13.1. 1-.1. 7.
182. Cai EZ, Ang CH, Raju A, Tan KB, Hing ECH, Loo Y, et al. Creation of consistent burn wounds: a rat model. *Archives of plastic surgery*. 2014;41(04):317-24.
183. Alhabbab RY. Enzyme Immunoassay (EIAs) and Enzyme-Linked Immunosorbent Assay (ELISA). *Basic Serological Testing*: Springer; 2018. p. 83-95.
184. Nasir GA, Awan SJ, Tariq A, Tanvir A, Maqbool T, Boota S, et al. POST-TREATMENT AUGMENTATION OF ANGIOGENESIS AND ANTI-OXIDATIVE INDEX OF ADULT STEM CELLS DERIVED FROM WHARTON'S JELLY. 2017.
185. Kakkar P, Das B, Viswanathan P. A modified spectrophotometric assay of superoxide dismutase. 1984.
186. Beutler E. Improved method for the determination of blood glutathione. *J lab clin Med*. 1963;61:882-8.
187. Sinha AK. Colorimetric assay of catalase. *Analytical biochemistry*. 1972;47(2):389-94.
188. Mahmood R, Mehmood A, Choudhery MS, Awan SJ, Khan SN, Riazuddin S. Human neonatal stem cell-derived skin substitute improves healing of severe burn wounds in a rat model. *Cell biology international*. 2019;43(2):147-57.
189. Khan NT. Therapeutic benefits of lemongrass and tea tree. *Environ Eng*. 2020;4:027-9.
190. Grazul-Bilska AT, Johnson ML, Bilski JJ, Redmer DA, Reynolds LP, Abdullah A, et al. Wound healing: the role of growth factors. *Drugs Today (Barc)*. 2003;39(10):787-800.
191. Häger SC, Nylandsted J. Annexins: players of single cell wound healing and regeneration. *Communicative & integrative biology*. 2019;12(1):162-5.
192. Comino-Sanz IM, López-Franco MD, Castro B, Pancorbo-Hidalgo PL. The role of antioxidants on wound healing: A review of the current evidence. *Journal of Clinical Medicine*. 2021;10(16):3558.

11/30/22, 10:12 AM

Turnitin

- [Assignments](#)
- [Students](#)
- [Grade Book](#)
- [Libraries](#)
- [Calendar](#)
- [Discussion](#)
- [Preferences](#)

Zoology



About this page

This is your assignment inbox. To view a paper, select the paper's title. To view a Similarity Report, select the paper's Similarity Report icon in the similarity column. A ghosted icon indicates that the Similarity Report has not yet been generated.

BA/ BSc January Defense 2023

Inbox | Now Viewing: new papers ▼

Submit File Online Grading Report | Edit assignment settings | Email non-submitters

<input type="checkbox"/>	Author	Title	Similarity	web	publication	student papers	Grade	response	File	Paper ID	Date
<input type="checkbox"/>	Nimra Tariq	Identification of Macroinvertebrates and...	5% <input type="text" value="5%"/>	2%	2%	1%			download paper	1966157550	29-Nov-2022
<input type="checkbox"/>	Nadia Khan	Anticancer and Skin Repair Potential of ...	9% <input type="text" value="9%"/>	7%	6%	2%			download paper	1966156600	29-Nov-2022
<input type="checkbox"/>	Sehar Munir	Evaluation of Skin Regeneration & Antiba...	9% <input type="text" value="9%"/>	7%	7%	2%			download paper	1966157059	29-Nov-2022
<input type="checkbox"/>	Fajjar Azhar	Wound healing and Antifungal Properties ...	10% <input type="text" value="10%"/>	6%	8%	1%			download paper	1966155397	29-Nov-2022
<input type="checkbox"/>	Larab Fatima	Determination of Heavy Metal Toxicity in...	12% <input type="text" value="12%"/>	5%	10%	3%			download paper	1966156240	29-Nov-2022
<input type="checkbox"/>	Bisma Noor	Determination of Heavy Metal Toxicity in...	12% <input type="text" value="12%"/>	5%	10%	3%			download paper	1966154357	29-Nov-2022
<input type="checkbox"/>	Faria Zainab	Effect of hermal plant on cellular viabi...	12% <input type="text" value="12%"/>	10%	8%	3%			download paper	1966155758	29-Nov-2022
<input type="checkbox"/>	Jamila Fatima	Efficacy of Pro-Biotic Supplementation o...	13% <input type="text" value="13%"/>	11%	6%	3%			download paper	1966155960	29-Nov-2022
<input type="checkbox"/>	Shazma Shazma	Toxicological Analysis of Indian Bullfro...	15% <input type="text" value="15%"/>	9%	11%	4%			download paper	1966157293	29-Nov-2022
<input type="checkbox"/>	Damna Tariq	Antifungal and injury regeneration pater...	16% <input type="text" value="16%"/>	12%	9%	5%			download paper	1966154976	29-Nov-2022

